document incorporate reference portion proxy statement registrant annual meeting stockholder hold file day conclusion registrant fiscal year end december incorporate reference iii annual report item business general bristolmyers squibb company refer bristolmyer squibb bms company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis operate segmentbiopharmaceutical additional information business segment refer item financial statementsnote business segment information compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession manufacture product united states puerto rico foreign country percentage revenue significant regioncountry follow year end december dollar millions united states europe japan china total revenue acquisition divestiture transition bms leadingedge specialty biopharmaceutical company focus exclusively discover develop deliver innovative medicine address unmet medical need transition encompass area business operation strategy divest diabete nonpharmaceutical business restructure alliance div certain mature brand product implement acquisition licensing strategy execute productivity transformation initiative significant divestiture include anticipate divestiture investigational hiv medicine half erbitux north america diabete business mead johnson acquisition licensing strategy acquire cardioxyl pharmaceuticals inc cardioxyl flexus biosciences inc flexus ipierian inc ipierian amylin pharmaceuticals inc amylin inhibitex inc inhibitex amira pharmaceuticals inc amira enter license collaboration arrangement transaction allow continue allow focus resource growth opportunity drive great longterm value disease standpoint focus follow core therapeutic area oncology immunooncology immunoscience cardiovascular disease fibrosis genetically define disease product pharmaceutical product include chemicallysynthesize drug small molecule increase portion product produce biological process typically involve recombinant dna technology call biologics small molecule drug typically administer orally form pill tablet drug delivery mechanism biologic typically administer patient injection infusion revenue come product follow therapeutic class virology include hiv infection oncology immunoscience cardiovascular neuroscience pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity business focus innovative biopharmaceutical product rely patent right form regulatory protection maintain market exclusivity product european union country patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion patent right regulatory form exclusivity refer intellectual property product exclusivity discussion impact generic competition business refer generic competition follow chart show key product year early basic exclusivity loss patent right datum exclusivity occur currently estimate occur japan china sell pharmaceutical product country datum provide countrybycountry basis individual country revenue significant outside japan china instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical trial datum obtain marketing approval prior expiration datum exclusivity estimate market exclusivity period product purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate follow schedule present revenue key product estimate basic exclusivity loss japan china total revenue product past currently estimate year basic exclusivity loss dollar million eua japan china virology baraclude entecavir hepatitis franchise reyataz atazanavir sulfate franchise sustiva efavirenz franchise oncology empliciti elotuzumabi erbitux cetuximab opdivo nivolumab sprycel dasatinib yervoy ipilimumab neuroscience abilify aripiprazole immunoscience orencia abatacept cardiovascular eliquis apixaban note currently estimate early year basic exclusivity loss include statutory extension exclusivity grant instance able obtain additional month exclusivity product base pediatric extension certain instance laterexpire patent cover particular form composition drug method manufacturing method drug patent result favorable market position product product exclusivity predict assure healthcare law enact qualifying biologic product receive year datum exclusivity biosimilar enter market describe detail intellectual property product exclusivity indicate brand name product trademark own bms specific trademark ownership information include exhibit index currently market product country region indicate uncertainty china exclusivity law result generic competition china market uncertainty china exclusivity law apotex inc actavis group ptc ehf generics limited mylan unnamed company file opposition european patent office epo seek revocation european patent patent cover dasatinib active ingredient sprycel patent schedule expire april exclude potential term extension january opposition division epo revoke patent company appeal epos decision epo board appeal patent remain force pende outcome appeal epos decision intend pursue legal option defend intellectual property right future infringement refer note legal proceeding contingency information reference include member states european union year end december basic patent application file current member state list product instance date basic exclusivity loss different member states country basic patent obtain datum protection available baraclude september teva pharmaceuticals launch generic version baraclude experience negative impact net product sale baraclude begin fourth quarter action follow decision june court appeal federal circuit uphold low court decision invalidate baraclude patent february supreme court deny company petition writ certiorari accordingly case conclude information patent litigation matter refer item financial statementsnote legal proceeding contingency baraclude composition matter patent expire exclusivity period relate daklinza brand composition matter cover daclatasvir japan expire include grant patent term extension reyataz data exclusivity expire project market exclusivity expire sustiva exclusivity period relate sustiva brand include exclusivity relate combination therapy composition matter patent efavirenz expire method use patent treatment hiv infection expire september pediatric exclusivity grant provide additional month period exclusivity add term patent list orange book october company announce successfully resolve outstanding patent litigation relate efavirenz loss exclusivity efavirenz expect occur december sustiva exclusivity period relate sustiva brand include exclusivity relate combination therapy market exclusivity sustiva expire november countries data exclusivity sustiva expire empliciti commercialization agreement abbvie inc abbvie empliciti information arrangement abbvie refer alliance item financial statementsnote alliance abbvie own patent cover elotuzumab composition matter expire exclude potential patent term extension japan china exclude potential patent term extension japan erbitux biologic product approve biologics license application bla datum exclusivity expire patent specifically claim composition matter cetuximab active ingredient erbitux company transfer right include commercialization manufacturing responsibility erbitux north america lilly return salesbase royalty information arrangement lilly refer alliance item financial statementsnote alliance erbitux japan exclusivity period base regulatory datum protection bm transfer cocommercialization right japan merck kgaa exchange salesbased royalties opdivo jointly patent ono pharmaceutical ltd ono cover nivolumab composition matter expire exclude potential patent term extension exclude potential patent term extension composition matter patent cover nivolumab japan expire include grant patent term extension sprycel patent term extension grant extend term basic composition matter patent cover dasatinib june company enter settlement agreement apotex patent infringement suit cover monohydrate form dasatinib apotex launch generic dasatinib monohydrate abbreviate new drug application product september early certain circumstance orphan drug exclusivity expire yervoy exclusivity period base regulatory datum protection datum exclusivity expire patent cover ipilimumab composition matter currently expire exclude potential patent term extension yervoy exclusivity period base regulatory datum protection datum exclusivity expire patent cover ipilimumab composition matter currently expire exclude potential patent term extension yervoy japan exclusivity period base regulatory datum protection patent cover ipilimumab composition matter currently expire japan exclude potential patent term extension abilify commercialization right abilify terminate april june orencia series patent cover abatacept method use patent term extension grant composition matter patent extend term patent datum exclusivity expire method use patent expire orencia composition matter patent covering abatacept expire majority country apply supplementary protection certificate pediatric extension supplementary protection certificate protection protection certificate grant datum exclusivity expire method use patent expire orencia japan exclusivity period base regulatory data protection eliquis composition matter patent cover apixaban expire february exclude potential patent term extension august receive petition inter part review composition matter patent covering apixaban file united states patent trademark office coalition affordable drug information patent litigation matter refer item financial statementsnote legal proceeding contingency eliquis japan composition matter patent cover apixaban expire apply supplementary protection certificate supplementary protection certificate grant expire datum exclusivity expire composition matter cover apixaban japan expire include grant patent term extension summary indication product partner thirdparty manufacturing arrangement product applicable japan baraclude baraclude potent selective inhibitor hepatitis virus approve food drug administration fda treatment chronic hepatitis virus infection baraclude discover develop internally bulk active entecavir manufacture company party product finish facility hepatitis franchise daklinza daclatasvir dcv oral small molecule nsa replication complex inhibitor treatment hepatitis virus infection hcv approve fda use gilead sciences inc gilead sofosbuvir genotype sunvepra asunaprevir asv oral small molecule protease inhibitor treatment hcv dual regimen dcvasv japan manufacture bulk requirement daclatasvir finish product facility obtain bulk requirement asunaprevir thirdparty manufacturer finish product thirdparty facility reyataz franchise reyataz protease inhibitor treatment hiv reyataz franchise include reyataz combination therapy evotaz atazanavir cobicistat oncedaily single tablet drug regiman combine reyataz gilead tybost cobicistat treatment hiv infection adult develop atazanavir worldwide license novartis pharmaceutical corporation novartis royalty pay base percentage net product sale entitle promote reyataz use combination norvir ritonavir nonexclusive license agreement abbvie amend royalty pay base percentage net product sale licensing agreement gilead evotaz approve january july manufacture bulk requirement atazanavir finish product facility sustiva franchise sustiva nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise include sustiva antiretroviral drug treatment hiv bulk efavirenz include combination therapy atripla efavirenz emtricitabine tenofovir disoproxil fumarate oncedaily single tablet threedrug regimen combine sustiva gilead truvada emtricitabine tenofovir disoproxil fumarate information arrangement gilead refer alliance item financial statementsnote alliance right market efavirenz canada united kingdom france germany ireland italy spain license merck inc merck royalty base percentage revenue efavirenz market company japan obtain bulk requirement efavirenz party produce finished good facility supply party bulk efavirenz gilead responsible produce finished atripla product empliciti empliciti humanize monoclonal antibody approve fda treatment multiple myeloma alliance abbvie term alliance grant exclusive global right codevelop commercialize empliciti november fda approve empliciti treatment multiple myeloma combination therapy revlimid dexamethasone patient receive prior therapy revlimid product celgene corporation january committee medicinal product human use chmp european medicine agency ema adopt positive opinion recommend empliciti grant approval treatment multiple myeloma manufacture bulk requirement elotuzumab finish product facility erbitux erbitux biological product igg monoclonal antibody design exclusively target block epidermal growth factor receptor egfr express surface certain cancer cell multiple tumor type normal cell erbitux approve combination irinotecan treatment patient egfrexpresse metastatic colorectal cancer mcrc fail irinotecanbase regimen monotherapy patient intolerant irinotecan fda approve erbitux use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patient recurrent metastatic squamous cell carcinoma head neck prior platinumbase therapy fail fda approve erbitux firstline recurrent locoregional metastatic head neck cancer combination platinumbase chemotherapy fluorouracil exclusive distribution right north america cetuximab grant company imclone system incorporate imclone predecessor company imclone llc whollyowne subsidiary eli lilly company lilly alliance lilly october transfer erbitux right north america lilly include commercialization manufacturing responsibility return salesbased royalty information arrangement lilly refer alliance item financial statementsnote alliance opdivo opdivo biological product fully human monoclonal antibody bind program death receptor natural killer nkt cell fda approve opdivo previously untreated patient metastatic melanoma previously treat patient advance renal cell carcinoma previously treat nonsquamous nsq squamous nonsmall cell lung cancer nsclc opdivo receive approval previously treat nsclc firstline previously treat unresectable metastatic melanoma opdivoyervoy ipilimumab regimen approve fda treatment braf wild type unresectable metastatic melanoma ongoing potentially registrational trial opdivo head neck cancer hodgkin nonhodgkin lymphoma bladder cancer tumor type refer alliance item financial statementsnote alliance discussion arrangement ono opdivo japan south korea taiwan obtain bulk requirement opdivo party finish product facility sprycel sprycel multitargete tyrosine kinase inhibitor approve firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib mesylate gleevec trademark novartis sprycel internally discover alliance otsuka pharmaceutical ltd otsuka information alliance otsuka refer alliance item financial statementsnote alliance manufacture bulk requirement dasatinib finish product facility yervoy yervoy biological product monoclonal antibody treatment patient unresectable metastatic melanoma yervoy approve japan fda approve yervoy adjuvant treatment patient cutaneous melanoma information research development yervoy refer research development yervoy discover medarex codevelope company medarex subsidiary bulk ipilimumab manufacture company party product finish facility thirdparty facility abilify abilify atypical antipsychotic agent adult patient schizophrenia bipolar mania disorder major depressive disorder abilify pediatric use schizophrenia bipolar disorder bms right abilify expire april countries june information arrangement otsuka refer alliance item financial statementsnote alliance orencia orencia biological product fusion protein novel immunosuppressive activity target initially adult patient moderately severely active rheumatoid arthritis inadequate response certain currently available treatment orencia available intravenous subcutaneous formulation europe japan refer alliance item financial statementsnote alliance discussion collaboration ono orencia japan bulk abatacept manufacture company party finish formulation product facility eliquis eliquis oral factor inhibitor target stroke prevention atrial fibrillation prevention treatment venous thromboembolic vte disorder apixaban discover internally alliance pfizer inc pfizer information alliance pfizer refer item financial statementsnote alliance apixaban manufacture company party product finish facility research development invest heavily research development believe critical longterm competitiveness major facility new jersey expand exist californiabase research facility announce future plan open new site massachusetts research activity connecticut facility phase year research development carry facility world include belgium india japan site supplement internal drug discovery development program alliance collaborative agreement help bring new product pipeline drug development engage service physician hospital medical school research organization worldwide conduct clinical trial establish safety effectiveness new product management continue emphasize leadership innovation productivity quality strategy success research development activity concentrate research development effort follow disease area significant unmet medical need immunooncology oncology immunoscience cardiovascular fibrotic disease genetically define disease continue analyze selectively pursue promising lead area addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug include phase phase phase iii clinical trial design specifically support new drug application particular indication assume trial successful phase clinical trial involve small number healthy volunteer patient suffer indicate disease test safety proper dosing phase clinical trial involve large patient population investigate effect efficacy optimal dosage drug candidate phase iii clinical trial conduct confirm phase result significantly large patient population long term provide reliable conclusive datum safety efficacy drug candidate process typically take fourteen year approximately year spend phase iii latestage development consider program phase iii significant program program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation drug development time consume expensive risky average chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate approximately compound enter phase development fail achieve regulatory approval failure rate compound enter phase development approximately compound enter phase iii development approximately total research development expense include cost discovery research preclinical development early latestage clinical development drug formulation postcommercialization medical support market product proportionate allocation enterprisewide cost appropriate cost research development spend billion billion billion include payment thirdparty collaboration contract end employ approximately people activity include substantial number physician scientist hold graduate postgraduate degree higherskille technical personnel manage program portfolio basis invest resource stage research development early discovery latestage development continually evaluate portfolio asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development program represent approximately annual expense year individual investigational compound market product represent expense year opdivo list investigational compound phase iii clinical trial investigational compound ultimately market product depend result clinical study competitive landscape potential product market manufacturing process necessary produce potential product commercial scale factor assurance seek regulatory approval compound approval sought obtain assurance compound approve commercially successful stage development determine intellectual property issue patent protection available investigational compound datum january immuno genetically define oncology oncology immunoscience cardiovascular fibrotic disease disease virology phase phase phase phase phase phase anticsf antifucosyl anticd factor xia inhibitors galectin inhibitorf antietauj antigitr antiherd anticdl par antagonist pegfgf antimyostatin antilag bet inhibitor btk inhibitor lirilumab antikirb mesothelinadc tyk inhibitor urelumab ulocuplumab anticd anticxcr antipdl phase phase phase phase bms lulizumab bms hiv maturation anticd ikur inhibitor lpa antagonistg inhibitork nitroxyl donore pegfgfh pentraxini phase iii phase iii prostvacc beclabuvir bms hiv attachment inhibitork exclusively license prime therapeutics inc exclusively license innate pharma obtain exclusive option license bavarian nordic obtain exclusive license acquire fstar alpha ltd obtain acquisition cardioxyl pharmaceuticals inc obtain exclusive option acquire galecto biotech obtain acquisition amira pharmaceuticals inc refer item financial statementsnote goodwill intangible asset additional information exclusively license ambrx inc obtain exclusive warrant acquire promedior inc obtain acquisition ipierian inc pende sale viiv healthcare additional information latestage investigational compound phase iii clinical trial regulatory review potential indication patent coverage highlight include patent term patent term extension grant beclabuvir beclabuvir oral small molecule nonnucleoside nsb inhibitor regulatory review japan use combination dcv asv treatment hcv patent cover beclabuvir composition matter expire bms bms investigational compound study hiv show antiviral activity hiv infect individual attachment inhibitor distinct mode action entry inhibitor prevent entry hiv host cell follow attachment bms prodrug metabolize active basic compound hold patent cover bms composition matter expire november bms expect sell viiv healthcare half prostvac prostvac bavarian nordic investigational phase iii prostatespecific antigen psatargete cancer immunotherapy development treatment asymptomatic minimally symptomatic metastatic castrationresistant prostate cancer bm exclusive option license commercialize prostvac follow table list potential additional indication andor formulation key marketed product potentially registrational trial currently regulatory review key market product potential indication andor formulation hepatitis franchise combination antiviral treatment hcv empliciti additional indication firstline multiple myeloma opdivo additional indication melanoma renal cell carcinoma rcc lung cancer hodgkin nonhodgkin lymphoma head neck cancer bladder cancer glioblastoma hepatocellular carcinoma gastric cancer esophageal cancer monotherapy andor combination yervoy orencia additional indication lupus nephritis psoriatic arthritis early autoinjector device eliquis pediatric vte treatment follow key development currently expect occur respect significant pipeline program outcome timing expect development dependent number factor include thing availability datum outcome certain clinical trial acceptance presentation certain medical meeting andor action health authority undertake obligation publicly update information result new information future event hepatitis franchise datum available clinical trial potential approval additional indication empliciti potential approval multiple myeloma japan data available phase iii study firstline multiple myeloma opdivo potential approval nsq nsclc opdivoyervoy combination melanoma rcc datum available potentially registrational clinical trial hodgkin nonhodgkin lymphoma head neck cancer bladder cancer glioblastoma lung cancer potential submission tumor base registrational trial alliance enter alliance party transfer right develop manufacture market andor sell pharmaceutical product own party alliance include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint venture alliance involve share research development cost risk incur research development expense compound lead revenuegenerate product reduce profitability alliance product generally low profit alliance product share alliance partner actively pursue arrangement view alliance important complement discovery development commercialization activity alliance party right manufacture market andor sell pharmaceutical product contain customary early termination provision typically find agreement kind generally base material breach agreement party bankruptcy voluntary involuntary party product safety concern notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination notice period generally available involuntary bankruptcy petition file dismiss material breach party occur cure alliance agreement permit terminate cause typically exercisable substantial advance write notice exercisable specify period time elapse alliance agreement sign alliance typically contain provision provide party right terminate alliance general retain right product bring alliance party party intellectual property alliance terminate loss right product market sell pursuant alliance material result operation cash flow material financial condition liquidity customary pharmaceutical industry term alliance generally coextensive exclusivity period vary countrybycountry basis significant current alliance currently market product investigational compound describe refer item financial statementsnote alliance additional information alliance agreement otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify exclude certain asian country portion agreement expire april agreement expire country june nonus country exclusive right sell abilify agreement expire later april loss exclusivity country bm receive share net sale abilify base tiere structure bms otsuka alliance sprycel japan oncology territory february copromotion agreement otsuka terminate japan ixempra ixabepilone include alliance prior bms divestiture business fee pay otsuka base combined annual net sale sprycel ixempra oncology territory include post divestiture ixempra sale gilead joint venture gilead develop commercialize atripla canada europe company gilead share responsibility certain activity relate commercialization atripla canada certain european country gilead recognize atripla revenue canada countries europe alliance revenue recognize atripla include bulk efavirenz component atripla calculate differently follow loss exclusivity sustiva alliance revenues defer related alliance receivable recognize atripla sell thirdparty customer collaboration agreement govern commercialization atripla canada continue terminate mutual agreement party describe event material breach party collaboration agreement nonbreache party terminate agreement breach party cure material breach party agree desirable practicable withdraw combination product market commercialize time generic version party component product launch party right terminate collaboration agreement control joint venture commercialization combination product canada year terminate party continue receive percentage net product salesbase contribution bulk component atripla retain right product europe follow loss exclusivity sustiva effective january percentage atripla net sale europe recognize bms equal difference average net selling price atripla truvada alliance continue europe party terminate arrangement patent expiration occur atripla truvada sustiva enter licensing agreement gilead develop commercialize fixeddose combination contain reyataz gileads cobicistat pharmacoenhance boost agent increase blood level certain hiv medicine potentially allow pill daily dose evotaz approve fda january european commission july lilly bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux canada japan october bms transfer right erbitux north america lilly exchange salesbase royalty transfer right include limited commercialization manufacturing responsibility bms share right erbitux japan agreement lilly merck kgaa receive pretax profit merck kgaas net sale erbitux japan share equally lilly bm transfer cocommercialization right japan merck kgaa exchange sale base royalties abbvie bms abbvie alliance empliciti term alliance bms grant exclusive global right codevelop commercialize empliciti pdl biopharma inc abbvie party codevelope product abbvie fund global development cost bms solely responsible supply distribution sale marketing activity alliance principal end customer product sale abbvie share profit loss pay tiere royalty net sale empliciti outside addition abbvie entitle receive milestone payment bms certain regulatory event sale threshold achieve astrazeneca february sell astrazeneca plc astrazeneca diabetes business comprise global alliance include right ownership onglyza farxiga bydureon byetta symlin myalept astrazeneca terminate exist alliance agreement connection sale enter new agreement include transitional service agreement supply agreement development agreement supply agreement continue manufacture responsibility onglyza kombiglyze farxiga pfizer company pfizer party worldwide codevelopment cocommercialization agreement eliquis pfizer fund development cost depend study company share commercialization expense profit loss equally global basis certain country pfizer commercialize eliquis pay bms compensation base percentage net sale ono bms principal end customer product sale exclusive right develop manufacture commercialize opdivo territory worldwide japan south korea taiwan ono responsible development commercialization prior arrangement describe ono entitle receive royalty follow regulatory approval territory exclude country list royalty rate net sale north america applicable territory subject customary adjustment alliance arrangement expand july establish collaboration activity japan south korea taiwan pertain opdivo bms compound include yervoy lirilumab urelumab bms antilag party right obligation jointly develop commercialize compound bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono alliance codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay party sale partys assign customer alliance bms reckitt benckiser group plc reckitt start threeyear alliance overthecounterproduct sell primarily mexico brazil reckitt receive right sell distribute market product bms grant reckitt option acquire trademark inventory certain asset exclusively relate product end alliance period include bms manufacturing facility locate mexico price determine primarily base multiple net sale july reckitt notify bms exercise option substantially employee facility expect transfer reckitt closing expect occur license arrangement addition alliance describe inlicense outlicense arrangement respect inlicense agreement novartis reyataz merck efavirenz certain compound outlicense party development commercialization include obtain acquisition entitle receive milestone payment compound regulatory process royalty base net product sale product commercialize intellectual property product exclusivity license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory intellectual property right develop country provide certain nonpatent incentive development medicine example japan certain country regulatory intellectual property right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive extend market exclusivity period product patent term japan china provide minimum period time approval new drug regulatory agency rely innovators data approve competitor generic copy datum protection region china questionable datum protection law enforceable certain market patent protection form market exclusivity expire datum protection particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data exclusivity basis competitor safety efficacy datum drug drug identical market innovator specific aspect law govern market exclusivity datum protection pharmaceuticals vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term innovator depend number factor extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical company file new drug application nda medicine biological product bla file type application file affect regulatory exclusivity right chemical product competitor seek launch generic substitute chemical innovative drug file abbreviate new drug application anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right addition benefit patent protection certain innovative pharmaceutical product receive period regulatory exclusivity nda designate orphan drug receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use company earn month additional exclusivity drug specific clinical trial conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical entitle year regulatory data protection competitor file fda approval generic substitutes innovators patent challenge describe generic manufacturer file anda fourth year fiveyear datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation drug new indication basis new clinical trial receive year datum protection formulation indication biologic product healthcare legislation enact create approval pathway biosimilar version innovative biological product previously exist prior time innovative biologic essentially unlimited regulatory exclusivity new regulatory mechanism fda approve product similar generic copy innovative biologic basis extensive datum require bla innovator market product year manufacturer file application approval biosimilar version innovator product application approval biosimilar file year approval innovator product qualify innovative biological product receive year regulatory exclusivity mean fda approve biosimilar version year innovative biological product approve fda law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity european union patent pharmaceutical product generally enforceable extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum maa ema ema evaluate maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain country process place simultaneously product market country process complete company market new product pricing reimbursement procedure month year complete product marketing authorization file octobernovember subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority market authorization application approve generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment product file prior octobernovember year period datum protection centralize procedure period year mutual recognition procedure depend member state contrast patent list regulatory authority generic version pharmaceutical product approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property datum protection addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity china china medicines new chemical entity generally afford year datum exclusivity approve indication dosage uncertainty china exclusivity law result generic competition china market generic copy receive regulatory approval datum exclusivity patent expiration currently unlike china patent term restoration compensate patent term lose regulatory process general chinese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity rest world country outside japan china wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply world trade organization wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor marketing distribution customer promote appropriate use product directly healthcare professional provider doctor nurse practitioner physician assistant pharmacist technologist hospital pharmacy benefit manager pbms manage care organization mcos provide information appropriate use product consumer directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceutical refer government regulation price constraint field sale medical organization explain risk benefit approve use product medical professional work gain access product formulary reimbursement plan list recommend approve medicine product include medicare plan provide information clinical profile product marketing sale prescription pharmaceutical limit approve use particular product continue develop scientific datum information product provide information response unsolicite inquiry doctor medical professional manage care organization operation include marketing sale organization product marketing organization support sale force responsible sell product market organization focus certain class customer manage care entity certain type marketing tool digital consumer communication sale force focus communicate information new product new use establish product promotion physician increasingly target physician specialist treat patient need medicine product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross revenue large pharmaceutical wholesaler percentage global gross revenue follow mckesson corporation amerisourcebergen corporation cardinal health inc business inventory management agreement ima substantially direct wholesaler distributor customer allow monitor wholesaler inventory level require wholesaler distributor maintain inventory level month demand ima include large wholesaler expire december subject certain termination provision number define country outside establish scale distributor model medically necessary drug available patient continue marketing authorization trademark product contract service fullservice distributor provide distribution logistic regulatory pharmacovigilance sale advertising promotion certain product sale distributorbase country represent approximately company total revenue competition market compete generally broad base highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service research development new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product revenue impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale generic competition big competitive challenge face generic pharmaceutical manufacturer regulatory approval process exempt generic costly timeconsuming clinical trial demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far research development researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion revenue product short period time rate revenue decline product expiration exclusivity vary country general decline market rapid develop country observe rapid decline number country decline develop country tend rapid develop country rate revenue decline expiration exclusivity historically influence product characteristic example drug large patient population prescribed key primary care physician tend experience rapid decline drug specialized area medicine oncology drug complex manufacture sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity refer intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment manage care organization growth mcos major factor healthcare marketplace half population participate version manage care mco include medical insurance company medical plan administrator healthmaintenance organization medicare prescription drug plan alliance hospital physician physician organization organization consolidate few large entity enhance purchasing strength importance successfully compete business mcos demonstrate product offer medical benefit cost advantage compare form care new product introduce compete product market product later develop competitor note generic drug exempt costly timeconsuming clinical trial demonstrate safety efficacy lower cost brandname drug mcos focus primarily immediate cost drug favor generic reason government encourage use generic alternative brandname drug healthcare program law generally allow case require pharmacist substitute generic drug rate government procedure essentially equivalent brandname drug substitution prescribe physician expressly forbid exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco formulary government regulation price constraint pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act fdc act federal statute regulation state statute regulation law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment particular importance fda jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market fda mandate drug manufacture package label conformity current good manufacturing practice cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw delay product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject prescription drug marketing act pdma fdc act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion medicine price base number factor include value scientific innovation patient society context overall health care spend economic factor impact health care system ability provide appropriate sustainable access necessity sustain investment innovation platform address unmet medical need central price clinical value innovation bring market current landscape alternative treatment option goal ensure appropriate patient access innovation sustain investment innovative platform continue explore innovative pricing approach ensure patient access medicine enhance patient access medicine priority focus offer creative tiere pricing voluntary licensing reimbursement support patient assistance program optimize access protect innovation advocate sustainable healthcare policy infrastructure leverage advocacypayer input utilize partnership appropriate improve access care supportive service vulnerable patient partnership demonstration project fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain drug labeling change relate safety mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical trial prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program office inspector general department health human service oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer oig guidance include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth oig guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement agency procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda approval approval obtain product approval product comparable regulatory authority country outside case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country market outside operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut method cost control countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing market germany government set pricing restriction launch pricing freedom subsequently limited operation profit price control plan operation reference price system germany company face significant delay market access new product mainly france spain italy belgium year elapse new medicine available national market additionally member states regularly impose new additional cost containment measure pharmaceutical volume discount cost cap cost sharing increase excess prior year cost individual product aggregate market level spend outcomebase pricing scheme free product portion expect therapy period recent year italy example impose mandatory price decrease existence price differential different national pricing reimbursement law lead significant parallel trade flow healthcare industry subject governmentimposed regulation authorize price price control continue impact total revenue participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate government program specify discount certain government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase result patient protection affordable care act reconciliation bill contain package change healthcare bill experience continue experience additional financial cost certain change business example minimum rebate medicaid drug sale increase percent percent medicaid rebate extend drug riskbase medicaid manage care plan addition extend discount certain critical access hospital cancer hospital cover entity require expansion drug pricing program public health service act require provide percent discount brandname drug patient fall medicare coverage gap refer donut hole pay annual nontaxdeductible fee federal government base allocation market share brand drug sale certain government program include medicare medicaid department veterans affairs department defense tricare discussion rebate program refer item management discussion analysis financial condition result operation total revenue critical accounting policy source availability raw material general purchase raw material supply require production product open market product purchase raw material supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate raw material supply risk inventory management alternative source strategy discussion source refer manufacture quality assurance discussion particular product manufacture quality assurance operate manage manufacturing network manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical production process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval maintain operate flexible manufacturing network consist internal external resource minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing refer government regulation price constraint pharmaceutical manufacturing facility locate puerto rico france italy ireland japan mexico china require significant ongoing capital investment maintenance compliance increase regulatory requirement addition product line change year expect continue modification exist manufacturing network meet complex processing standard require newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation fda approve large scale multiproduct bulk biologic manufacturing facility deven massachusetts continue capital investment facility build new largescale biologic manufacturing facility cruiserath ireland rely party manufacture supply portion active ingredient necessary manufacture product include baraclude sustiva franchise yervoy opdivo reyataz orencia eliquis begin october follow transfer right erbitux north america lilly lilly assume manufacturing responsibility erbitux maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier manufacturing operation interrupt additional protection case step maintain approve backup source available example rely capacity devens massachusetts facility capacity available party contract manufacturer manufacture orencia thirdparty manufacturer rely exist future product unable maintain stable supply product operate sufficient capacity meet order requirement comply government regulation manufacturing pharmaceutical meet complex processing requirement biologic business performance prospect negatively impact additionally thirdparty supplier experience extend plant shutdown substantial unplanned increase demand suspension manufacture regulatory reason experience interruption supply certain product product shortage production resume expand connection divestiture license arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party addition liability arise failure supply product agreement arrangement require invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility planning manufacturing distribution maintain qualityassurance procedure relate quality integrity technical information production process control production process involve detailed specification ingredient equipment facility manufacturing method process packaging material labeling perform test stage production process final product ensure product meet regulatory requirement standard test involve chemical physical chemical analyse microbiological testing combination analyse quality control provide business unitsite quality assurance group monitor exist manufacturing procedure system subsidiary thirdparty supplier environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment health safety group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis expend approximately million million million capital project undertake specifically meet environmental requirement addition invest project reduce resource use energy water believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include comprehensive environmental response compensation liability act cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify potentially responsible party prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter refer item financial statementsnote legal proceeding contingency employee december employ approximately people foreign operation significant operation outside conduct subsidiary distributor discussion total revenue geographic area refer item management discussion analysis financial condition result operationstotal revenue international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product depend direction change relative dollar foreign currency value increase decrease report dollar value net asset result operation change foreign exchange rate net unfavorable impact growth rate revenue predict certainty future change foreign exchange rate effect growth rate revenue attempt mitigate impact operational mean financial instrument refer discussion item quantitative qualitative disclosure market risk item financial statementsnote financial instrument fair value measurement bristolmyer squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material securities exchange commission sec information relate corporate governance bristolmyer squibb include principle integrity code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available website investorscorporate governance caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsstockholder service caption addition information sustainability program available website responsibility caption incorporate reference certain information part proxy statement annual meeting stockholder sec allow disclose important information refer manner refer information proxy statement annual meeting stockholder annual report available website investorssec filing caption march item risk factor factor describe significantly negatively affect business prospect financial condition operating result credit rating cause trading price common stock decline additional risk uncertainty presently know risk currently consider immaterial impair operation financial condition face intense competition manufacturer include innovative medicine lowerprice generic product bms dependent market access uptake expansion market brand new product introduction new indication product extension promotional activity alliance partner deliver future growth competition keen include lowerprice generic increasingly aggressive generic commercialization tactic low price company product real perceive superior efficacy benefit safety risk profile differentiate factor iii technological advance patent attain competitor clinical study result product competitor product affect value proposition product business combination competitor major thirdparty payer compete interest external partnership develop bring new product market lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value realize market exclusivity period country market exclusivity expire generic version approve market biosimilar introduce compete product usually substantial rapid decline product revenue market exclusivity product base patent right certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain patent intellectual property right limitation use loss right material country include certain member state basic patent protection product exist certain country historically offer right obtain specific type patent andor licensor file country addition patent environment unpredictable validity enforceability patent predict certainty absent relevant patent protection product datum exclusivity period expire generic version approve market generic biosimilar product manufacturer group seek financial gain increasingly seek challenge patent expire face earlierthanexpecte competition product time patent cover key product likely continue subject patent litigation case manufacturer seek regulatory approval submit clinical trial datum obtain marketing approval choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation assurance particular product enjoy market exclusivity time period appear estimate disclose form addition country india allow competitor manufacture sell compete generic product negatively impact protection afford company lowerprice biosimilar bms biologic product compete biologic negatively impact volume price increase pricing pressure restriction abroad manage care organization institutional purchaser government agency program negatively affect revenue profit margin product continue subject increase pressure portfolio market access pricing discount restriction region world include rule practice manage care organization institutional governmental purchasers judicial decision change law regulation federal healthcare program medicare medicaid healthcare reform government action inquiry iii potential impact change pharmaceutical reimbursement increase pricing pressure medicare formulary medicare reimbursement rate commercial formulary general reimbursement delay government price erosion mechanism europe country result deflation pharmaceutical product pricing collection delay governmentfunde public hospital outside vii impact pricing parallel trade border viii development technology andor industry practice impact reimbursement policy practice thirdparty payer inhibited market access real perceive difference value proposition product compare compete product thirdparty royalty represent significant percentage pretax income operate cash flow enter arrangement entitle potential royalty party outlicense intellectual property commercialization right salesbase contingent proceed relate divestiture business arrangement minimal continue involvement contribute financial success activity royalty continue represent significant percentage pretax income include royalty relate sanofi alliance outlicense intellectual property contingent proceed result divestiture diabete erbitux business pretax income generate royalty approximately million pretax income adversely affect royalty stream decline future period failure execute business strategy adversely impact growth profitability able consistently maintain rich pipeline internal program transaction party support future revenue growth competition pharmaceutical company acquisition product licensing opportunity intense able locate suitable acquisition target license partner reasonable price successfully execute transaction able successfully realize expect efficiency effectiveness change structure operation diversify specialty biopharmaceutical strategy unable support grow market product successfully execute launch newly approve product advance latestage pipeline manage change transformational issue manage cost effectively operate result financial condition negatively impact failure attract retain highly qualified personnel affect ability successfully develop commercialize product success largely dependent continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical research development governmental regulation commercialization competition qualified personnel biopharmaceutical field intense sure able attract retain quality personnel cost materially increase public announcement datum clinical study competitor news development relate competitor immunooncology product latestage compound cause significant volatility stock price development key immunooncology compound combination therapy delay discontinued stock price decline significantly focus effort resource certain disease area focus portfolio investor place heighten scrutiny product latestage compound particular opdivo important asset immunooncology portfolio announce multiple regulatory milestone opdivo fully human monoclonal antibody approve anticancer treatment nonsmall cell lung cancer renal cell cancer melanoma investigate tumor type combination approve cancer product yervoy expect receive news ongoing clinical trial health authority announcement datum clinical study competitor news development relate competitor immuno oncology product latestage compound opdivo cause significant volatility stock price furthermore announcement negative unexpected datum discontinuation development key immunooncology compound combination therapy delay anticipate timeline file regulatory approval significant advancement competitor likely cause stock price decline significantly assurance datum clinical study support file regulatory approval approve key immunooncology compound commercially successful approve indication experience difficulty delay development commercialization new product compound product appear promise development fail reach market expected optimal timeframe addition product extension additional indication approve develop commercialize new compound product include inherent risk uncertainty include efficacy safety concern delay deny regulatory approval delay challenge produce product commercial scale excessive cost manufacture failure enter implement optimal alliance development andor commercialization new product iii failure maintain consistent scope variety promise latestage product failure product achieve maintain commercial viability change regulatory approval process cause delay denial new product approval regulatory approval delay especially common product expect risk evaluation mitigation strategy require fda address significant riskbenefit issue inability bring product market significant delay expect approval relate launch date new product negatively impact revenue earning addition certain acquire pipeline program include inprocess research development iprd cancel believe commercial prospect reduce recognize material noncash impairment charge program example recognize million iprd impairment charge lpa antagonist recognize million iprd impairment charge peginterferon lambda finally lose key molecule intermediary compound library natural manmade disaster act sabotage negatively impact product development cycle business asset acquire future underperform able successfully integrate exist business continue support pipeline compound product obtain licensing acquisition future revenue profit cash flow acquire company product technology pipeline candidate materialize low product uptake delay miss pipeline opportunity inability capture expect synergy increase competition safety concern regulatory issue supply chain problem factor control substantial difficulty cost delay result integrate acquisition include manufacturing distribution sale marketing promotion information technology activity policy procedure process control compliance iii company culture compensation structure human resource activity tax consideration depend key product revenue cash flow earning historically derive majority revenue earning key product heavily dependent product past year dependence profitability certain product likely continue instance orencia eliquis sprycel hepatitis franchise represent approximately great consolidated revenue expect growth product opdivo eliquis increasingly important revenue base reduction revenue product significantly negatively impact revenue cash flow earning experience difficulty delay manufacture distribution sale product product supply relate patient access negatively impact thing product seizure recall force closing manufacture plant failure failure supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay failure sole source single source supplier provide necessary raw material supply finish good reasonable timeframe failure thirdparty manufacturer supply bulk active finished product time construction regulatory approval delay new facility expansion exist facility include intended support future demand biologic product opdivo vii failure meet new emerge regulation require product track distribution channel unique identifier verify authenticity supply chain viii manufacturing distribution issue include limit manufacturing capacity change type product produce biologic physical limitation business interruption disruption supply chain continuity include natural manmade disaster facility critical supplier change foreign law regulation negatively affect revenue profit margin subject new government law regulation negatively affect business operating result financial condition company additional healthcare reform initiative country include additional mandatory discount fee increase tax revenue country mean reduce debt change tax rate limit phasingout eliminate deduction tax credit modify tax collection process tax certain tax haven tax certain excess income intellectual property change rule earning repatriation change tax law iii new law regulation judicial governmental decision affect pricing drug reimbursement receivable payment access marketing jurisdiction change intellectual property law change accounting standard increase datum privacy regulation enforcement vii emerge new global regulatory requirement report payment value transfer healthcare professional viii potential impact importation restriction legislative andor regulatory change product labeling change market product result negative impact revenue profit margin regulatory authority need change label pharmaceutical product include product market year change result additional datum postmarkete study headtohead trial adverse event report study identify biomarker objective characteristic indicate particular response product therapy study postmarkete experience produce important additional information product new information add product label affect riskbenefit profile lead potential recall withdrawal decline revenue product liability claim additional information study identify portion patient population nonresponsive medicine high risk adverse reaction label change base study limit patient population study provide additional information sponsor sponsor competitor insurance company government institution manage care organization scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negatively impact revenue inventory return limit patient population go forward additionally certain study result especially headtohead trial affect product formulary listing adversely affect revenue adverse outcome legal matter negatively affect business current future lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute adverse decision litigation include product liability commercial case iii antibribery regulation foreign corrupt practice act bribery act include compliance ongoe reporting obligation government result settlement civil settlement reach company sec october recall withdrawal pharmaceutical product force closing manufacture plant failure fulfill obligation supply contract government customer product pricing promotional matter vii lawsuit claim assert investigation violation security antitrust federal state pricing consumer protection datum privacy law viii environmental health safety sustainability matter tax liability depend party meet contractual regulatory obligation rely supplier vendor outsource partner alliance partner party research develop manufacture commercialize copromote sell product manage certain marketing sell human resource finance information technology business unit functional service meet contractual regulatory obligation party locate market subject political social risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure critical party meet obligation include future royalty milestone payment adequately deploy business continuity plan event crisis andor satisfactorily resolve significant disagreement address factor material adverse impact company operation result addition party violate allege violate law regulation include local pharmaceutical code foreign corrupt practice act bribery act similar law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence illegal distribution sale party counterfeit version product steal product negative impact reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard patient receive counterfeit drug risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell brand addition theft inventory warehouse plant intransit properly store later sell unauthorized channel adversely impact patient safety reputation business increasingly dependent information technology system infrastructure face certain risk include cyber security datum leakage significant breakdown invasion corruption destruction interruption critical information technology system infrastructure workforce authorize access system unauthorized person negatively impact operation everincrease use evolution technology include cloudbase computing create opportunity unintentional dissemination intentional destruction confidential information store system nonencrypte portable medium storage device experience business interruption theft confidential information reputational damage industrial espionage attack malware cyberattack compromise system infrastructure lead datum leakage internally thirdparty provider aggregate impact operation financial condition material date target event nature expect continue possibly increase frequency invest industry appropriate protection monitor practice datum information technology reduce risk continue monitor system ongoing basis current potential threat assurance effort prevent breakdown breach thirdparty provider database system adversely affect business social medium platform present risk challenge inappropriate andor unauthorized use certain medium vehicle cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information employee patient healthcare professional stakeholder addition negative inaccurate post comment social network website damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce external medium channel lead information loss identify new point entry social medium continue expand present new challenge adverse change global regional local economic condition adversely affect profitability global economic risk pose significant challenge company growth profitability difficult mitigate world major economy hold historicallyhigh debt level experience slow growth high unemployment rate risk lie ahead include management debt european sovereign debt significant operation europe include manufacturing exposure customer credit risk europe south america market include governmentguaranteed hospital receivables market payment receive time addition future pension plan funding requirement continue sensitive global economic condition relate impact equity market expose commercial risk economic factor control pose significant challenge underlie profitability change foreign currency exchange interest tax rate material adverse effect operating result liquidity significant operation outside generate approximately revenue revenue earning cash flow expose risk strengthen dollar euro japanese yen chinese renminbi canadian dollar south korean difficult mitigate derivative financial instrument hedge certain underlying economic exposure financial instrument include derivative subject counterparty credit risk addition result operation negatively impact member country exit eurozone monetary union expose change interest rate ability access money market andor capital market impede adverse liquidity market condition occur debt rating pressure financial clinical expectation meet item unresolved staff comment item property principal executive office locate park avenue new york lease approximately square foot floor space lease approximately propertie country manufacture product worldwide location own manufacturing location aggregate square foot floor space geographic area follow december number location square feet united states europe rest world total portion manufacturing location property own lease research development administration storage distribution information property refer item businessmanufacture quality assurance item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference item safety disclosure applicable executive officer registrant list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve pleasure board director current position age employment history past year giovanni caforio senior vice president oncology immunology global commercialization chief executive officer director president pharmaceuticals member leadership team executive vice president chief commercial officer chief operating officer director company present chief executive officer director company charle bancroft chief financial officer company executive vice president chief financial officer present executive vice president chief financial officer company member leadership team emmanuel blin president general manager japan senior vice president head president global commercialization commercialization policy operation present senior vice president head commercialization policy operation member leadership team joseph caldarella present senior vice president corporate controller senior vice president corporate controller francis cuss bchir frcp senior vice president research executive vice president chief scientific officer present executive vice president chief scientific officer member leadership team john elicker senior vice president investor relation senior vice president public affairs investor present senior vice president public affairs investor relation relation member leadership team murdo gordon senior vice president access senior vice president head worldwide senior vice president oncology immunology market president pharmaceuticals member leadership team present senior vice president head worldwide market ann powell judge chief human resource officer shire pharmaceutical senior vice president global human resource present senior vice president global human resource member leadership team sandra leung general counsel corporate secretary executive vice president general counsel executive vice president general counsel corporate secretary member leadership team present executive vice president general counsel anne nielsen vice president associate general counsel senior vice president chief compliance senior vice president deputy general counsel ethic officer present senior vice president chief compliance ethic officer member leadership team louis schmukler senior vice president specialtybiotechnology operating unit pfizer president global manufacturing supply present president global manufacturing supply member leadership team paul von autenrie vice president chief information officer senior vice president enterprise service chief senior vice president chief information officer information officer present senior vice president enterprise service chief information officer member leadership team item market registrant common stock stockholder matter market price bristolmyer squibb common stock trade new york stock exchange nyse symbol bmy quarterly summary high low market price present high low high low common quarter second quarter quarter fourth quarter holder common stock number record holder common stock december number record holder base actual number holder register book date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company dividend board director declare follow quarterly dividend share pay period indicate common prefer quarter second quarter quarter fourth quarter december board director declare quarterly dividend share common stock pay february shareholders record january board director declare quarterly dividend share prefer stock payable march shareholders record february unregistere sale equity security use proceed follow table summarize surrender equity security month period end december total number share approximate dollar value average price purchase share total number pay publicly announce purchase period share purchaseda sharea plan programsb plan programsb dollar million share datum january february march month end march april june month end june july august september month end september october november december month end december month end december reflect share common stock surrender company satisfy tax withholding obligation connection vest award longterm incentive program board director authorize repurchase billion common stock june board director increase authorization repurchase common stock additional billion repurchase program expiration date consider future repurchase item select financial datum year financial summary amount million share datum income statement dataa total revenue continue operation net earning net earning attributable noncontrolle interest bms net earning common share attributable bms basic diluted average common share outstanding basic diluted cash dividend pay bms common prefer stock cash dividend declare common share financial position datum december cash cash equivalent marketable securitiesb total asset longterm debtb equity discussion item affect comparability result year refer item management discussion analysis financial condition result operationsnongaap financial measure include current noncurrent portion item management discussion analysis financial condition result operation executive summary bristolmyers squibb company refer bristolmyer squibb bms company global specialty biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease revenue increase result recently launch product hepatitis franchise include previously defer revenue france opdivo nivolumab continue sale growth eliquis apixaban impact partially offset change foreign currency rate expiration european union commercialization rights abilify aripiprazole competitive pressure result exclusivity loss factor baraclude entecavir reyataz atazanavir sulfate sustiva efavirenz certain market expirationtransfer certain licensing royalty right decrease gaap earning share eps high research development expense result upfront payment license asset acquisition investigational compound tax impact specify item contribute change effective tax rate include nontaxdeductible research development charge acquisition flexus biosciences inc flexus cardioxyl pharmaceuticals inc cardioxyl adjust specify item increase nongaap ep primarily high revenue highlight follow table summarize financial information year end december dollar million share datum total revenue total expense earning income taxis provision income taxis effective tax rate net earning attributable bms gaap nongaap dilute earning share gaap nongaap cash cash equivalent marketable security nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure refer nongaap financial measure significant product pipeline approval receive approval new medicine additional indication formulation currently market medicine include major market japan following summary significant approval receive product date approval japanese ministry health labour welfare manufacturing marketing approval patient december unresectable advanced recurrent nonsmall cell lung cancer nsclc receive ono pharmaceutical ltd ono food drug administration fda approval single agent treatment previously untreated november patient braf wildtype unresectable metastatic melanoma fda approval treatment previously treat patient advance metastatic renal cell carcinoma november rcc opdivo october fda approval treatment previously treat patient nonsquamous nsq nsclc approval treatment locally advanced metastatic squamous nsclc prior july chemotherapy approval treatment firstline previously treat unresectable metastatic melanoma june patient regardless braf status fda approval treatment patient advance nsclc progression platinum march base chemotherapy opdivo september yervoy ipilimumab fda approval treatment patient braf wildtype unresectable metastatic melanoma october fda approval adjuvant treatment patient cutaneous melanoma yervoy japanese ministry health labour welfare approval second line treatment unresectable july malignant melanoma fda approval treatment multiple myeloma combination therapy revlimid empliciti elotuzumab november dexamethasone patient receive prior therapy hepatitis portfolio fda approval use sofosbuvir treatment patient chronic hepatitis virus hcv july daklinza daclatasvir genotype refer product pipeline development development market product latestage pipeline strategy transition specialty biopharmaceutical company strategy design leverage reach resource major pharmaceutical company entrepreneurial spirit agility biotech firm focus discover develop deliver innovative medicine address unmet medical need strategic priority drive business performance maintain leadership immunooncology maintain diversified portfolio outside immunooncology continue discipline approach capital allocation business development priority develop new medicine follow core therapeutic area oncology immunooncology immunoscience cardiovascular disease fibrosis genetically define disease pioneer innovative medicine area immunooncology unlock bodys immune system battle cancer yervoy immunooncology agent introduce treatment metastatic melanoma announce significant clinical regulatory milestone opdivo program death receptor immune checkpoint inhibitor month opdivo approval metastatic melanoma late december work unprecedented speed fda receive additional approval indication different tumor type transform cancer care advanced nsclc melanoma rcc end opdivo approve country continue invest significantly deep pipeline innovative medicine cover broad array cancer enter collaboration agreement research develop opdivo approve investigational oncology agent combination regimen additionally enhance portfolio acquire right novel asset therapeutic area include cardiovascular disease fibrosis evolve commercial model grow market product portfolio manner consistent overall strategy oncology build rapid commercial acceptance opdivo revenue approximately million continued success yervoy sprycel dasatinib oncology remain strongly commit orencia abatacept eliquis revenue approximately billion receive approval daklinza use sofosbuvir treatment patient chronic hcv genotype continue support key brand virology franchise reyataz baraclude sustiva franchise december announce divestiture pipeline investigational human immunodeficiency virus hiv medicine viiv healthcare global specialist company exclusively dedicate find new medicine people live hiv transaction allow focus therapeutic area priority drive great longterm value look ahead continue implement biopharma strategy drive growth key brand execute new product launch invest diverse innovative pipeline include business development focus prioritize market increase investment biologic manufacturing capability maintain culture continuous improvement acquisition licensing arrangement acquisition licensing transaction allow focus resource growth opportunity drive great longterm value focus follow core therapeutic area oncology immunooncology immunoscience cardiovascular disease fibrosis genetically define disease significant transaction enter summarize kyorin pharmaceutical ltd kyorin december bms kyorin enter exclusive worldwide license agreement grant bms right develop manufacture commercialize kyorin fpr agonist program kyorin option collaborate bms development commercialization japan cardioxyl december bms acquire outstanding share cardioxyl privately hold biotechnology company focus discovery development novel therapeutic agent cardiovascular disease acquisition provide bms right cxl nitroxyl prodrug phase development acute decompensate heart failure prime therapeutics inc prime november bms prime enter exclusive worldwide licensing collaboration agreement development commercialization prime colony stimulate factor receptor csfr antibody program include fpa currently phase development immunology oncology indication bms responsible development manufacturing commercialization fpa subject prime option conduct certain study cost develop fpa pigment vilonodular synovitis pvns combination internal oncology pipeline asset prime retain option copromote agreement replace previous clinical collaboration agreement party promedior inc promedior september company purchase warrant give bms exclusive right acquire promedior gain worldwide right lead asset prm recombinant form human pentraxin protein phase development treatment idiopathic pulmonary fibrosis ipf myelofibrosis prm grant fast track designation orphan designation europe treatment addition prm grant orphan designation europe treatment ipf uniqure uniqure company enter collaboration license agreement uniqure grant bms exclusive license uniqure gene therapy technology platform specific collaboration target potential gene therapy product collaboration target develop uniqure platform develop disease party intend focus initially cardiovascular disease collaboration include uniqure proprietary gene therapy program congestive heart failure intend restore heart ability synthesize calcium sensor master regulator heart function improve clinical outcome patient reduce ejection fraction total company collaborate target include bms solely responsible global commercialization product collaboration august company select additional collaboration target company acquire million share uniqure separate tranche uniqure outstanding share immediately follow second acquisition company grant warrant company right purchase additional share share currently own bms equal uniqure oustande share immediately issuance exercise warrant condition designation bms certain number additional collaboration target payment bms uniqure relate fee collaboration license agreement flexus april company acquire outstanding share flexus privately hold biotechnology company focus discover develop novel anticancer therapeutic acquisition provide bms right preclinical small molecule idoinhibitor target immunotherapy potential combination bms immunooncology portfolio addition transaction include flexus idotdo discovery program include idoselective idotdo dual tdoselective compound novo nordisk novo nordisk march company acquire exclusive global license novo nordisk discovery biologics research program focus modulate innate immune system therapy autoimmune disease bavarian nordic bavarian nordic march company acquire exclusive option globally license commercialize prostvac bavarian nordics investigational phase iii prostate specific antigentargete cancer immunotherapy development treatment asymptomatic minimally symptomatic metastatic castrationresistant prostate cancer rigel pharmaceuticals inc rigel february company execute agreement rigel discovery development global commercialization cancer immunotherapy base rigel extensive portfolio small molecule tgf beta receptor kinase inhibitor collaboration focus develop new class therapeutic aim increase immune system activity cancer monotherapy combination immune checkpoint inhibitor include opdivo yervoy california institute biomedical research calibr january company enter worldwide research collaboration calibr develop novel small molecule antifibrotic therapy exclusive global license agreement allow company develop manufacture commercialize calibr preclinical compound result collaboration result operation total revenue composition change revenue follow year end december total revenue analysis change analysis change total foreign total foreign dollar million change exchangeb change exchangeb united states europe rest world othera total revenue include royalty alliancerelate revenue product sell regional commercial organization foreign exchange impact derive apply prior period average currency rate current period sale increase revenue result launch opdivo daklinza high demand eliquis sprycel partially offset expiration commercialization right abilify transfer erbitux north america average net selling price increase approximately refer product sale discussion additional information decrease revenue result diabete business divestiture february partially offset high demand eliquis yervoy sprycel high average net selling price approximately decrease europe revenue result unfavorable foreign exchange expiration commercialization right abilify june partially offset launch daklinza certain country quarter high demand eliquis revenue impact approximately million daklinza net product sale amount previously defer final pricing obtain france occur revenue continue negatively impact european country healthcare payer include government agency continue reduce healthcare cost action directly indirectly impose additional price reduction decrease europe revenue result expiration commercialization rights abilify june diabete business divestiture loss exclusivity sustiva november partially offset high demand eliquis yervoy orencia launch daklinza certain country quarter increase rest world revenue result launch daklinza sunvepra dual regimen japan quarter high demand eliquis partially offset unfavorable foreign exchange primarily japan increase rest world revenue result high demand key product particularly eliquis yervoy sprycel launch daklinza sunvepra dual regimen japan quarter partially offset diabetes business divestiture unfavorable foreign exchange primarily japan decrease revenue result expirationtransfer certain licensing royalty right increase revenue result high royalty mature brand overthecounter product alliance diabete product supply sale refer item financial statementsnote alliance discussion alliance single country outside contribute total revenue japan contribute total revenue recognize revenue net grosstonet adjustment describe critical accounting policy share certain abilify atripla revenue reflect net grosstonet adjustment alliance revenue present grosstonet adjustment table share abilify atripla grosstonet adjustment approximately billion billion billion grosstonet adjustment decrease expiration commercialization right abilify april activity end reserve balance significant category grosstonet adjustment follow rebate chargeback medicaid discount dollar million cash discount medicare rebate sale return adjustment total balance january provision relate sale current period prior period return payment foreign currency translation balance december provision relate sale current period prior period return payment foreign currency translation balance december reconciliation gross product sale net product sale exclude alliance revenue significant category grosstonet adjustment follow year end december dollar millions gross product sale grosstonet adjustment chargeback cash discount medicaid medicare rebate sale return rebate discount adjustment total grosstonet adjustment net product sale grosstonet adjustment rate primarily function change revenue mix contractual legislative discount rebate grosstonet adjustment increase chargeback cash discount increase primarily high product sale particularly eliquis opdivo medicaid medicare rebates increase primarily high product sale rebate rate particularly medicare eliquis medicaid medicare rebates increase primarily high medicare sale rebate rate eliquis high medicaid rebate virology product price increase limitation partially offset diabetes business divestiture february sales return reserve plavix reduce million million million consider factor include actual return experience estimate inventory level distribution channel accordance company policy product eligible return month prior month product expiration sale return reserve plavix material december rebate discount adjustment increase primarily additional rebate discount daklinza include approximately million obtain final pricing france amount defer march eliquis product revenue change attributable year end december change foreign exchange dollar million virology baraclude entecavir nonus hepatitis franchise daclatasvir asunaprevir nonus reyataz atazanavir sulfate franchise nonus sustiva efavirenz franchise nonus oncology empliciti elotuzumab erbitux cetuximab nonus opdivo nivolumab nonus sprycel dasatinib nonus yervoy ipilimumab nonus neuroscience abilify aripiprazole nonus immunoscience orencia abatacept nonus cardiovascular eliquis apixaban nonus mature product nonus change excess baraclude oral antiviral agent treatment chronic hepatitis revenue decrease period follow loss exclusivity september international revenue decrease unfavorable foreign exchange partially offset high demand certain country hepatitis franchise include daklinza nsa replication complex inhibitor revenue million million sunvepra asunaprevir protease inhibitor revenue million million daklinza launch july additional competition expect daklinza launch germany certain country quarter subsequently approve international market daklinza sunvepra dual regimen launch japan quarter international revenue include million previously defer revenue france recognize international revenue expect significantly decline increase competition primarily japan reyataz franchise protease inhibitor treatment hiv include reyataz include combination therapy evotaz atazanavir cobicistat revenue decrease period low demand result increase competition international revenue decrease period unfavorable foreign exchange low demand result increase competition sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla revenue decrease low demand result increase competition partially offset high average net selling price revenue increase high average net selling price partially offset low demand international revenue decrease period sustiva loss exclusivity europe november continue negatively impact demand average net selling price atripla revenue share empliciti humanize monoclonal antibody treatment multiple myeloma empliciti launch december erbitux monoclonal antibody design exclusively target block epidermal growth factor receptor express surface certain cancer cell multiple tumor type normal cell currently indicate use treatment patient certain type metastatic colorectal cancer squamous cell carcinoma head neck revenue decrease bms transferring right erbitux north america eli lilly company lilly october refer item financial statementsnote alliance discussion opdivo fully human monoclonal antibody bind program death receptor natural killer nkt cell approve continue investigate anticancer treatment revenue increase launch opdivo december treatment unresectable melanoma subsequent approval additional indication include nsq nsclc rcc rapid commercial acceptance opdivo year refer significant product pipeline highlights discussion additional opdivo approval opdivo launch japan september subsequently approve june treatment unresectable melanoma july treatment advance nsclc opdivo approve international market sprycel oral inhibitor multiple tyrosine kinase indicate firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate revenue increase period primarily high demand international revenue decrease unfavorable foreign exchange partially offset high demand international revenue increase primarily high demand partially offset unfavorable foreign exchange yervoy monoclonal antibody treatment patient unresectable metastatic melanoma revenue decrease low demand result introduction immunooncology product treat patient melanoma include opdivo revenue increase high demand international revenue decrease unfavorable foreign exchange international revenue increase high demand abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder revenue decrease expiration commercialization right april revenue increase primarily high average net selling price partially offset reduction share abilify revenue bms share abilify revenue international revenue decrease period follow expiration commercialization rights june otsuka pharmaceutical ltd principal end customer sale certain market orencia fusion protein indicate adult patient moderate severe active rheumatoid arthritis indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular juvenile idiopathic arthritis revenue increase period high average net selling price demand international revenue increase period primarily high demand subcutaneous formulation partially offset unfavorable foreign exchange eliquis oral factor inhibitor target stroke prevention nonvalvular atrial fibrillation nvaf prevention treatment venous thromboembolic vte disorder international revenue increase period high demand follow launch major market reduction risk stroke systemic embolism patient nvaf treatment vte international revenue impact unfavorable foreign exchange mature product include product include lose exclusivity major market diabete alliance product overthe counter brands royalty revenue revenue decrease period primarily diabetes business divestiture february international revenue decrease expirationtransfer certain licensing royalty right diabete business divestiture february unfavorable foreign exchange continue generic erosion international revenue decrease diabetes business divestiture continue generic erosion product partially offset high alliance revenue estimate endus demand pursuant securities exchange commission sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject minimis exception estimate level inventory distribution channel excess month hand follow product material result operation date indicate product estimate level inventory distribution channel excess month hand december international product estimate level inventory distribution channel excess month hand september dafalgan analgesic product sell principally europe month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily order pattern pharmacist france efferalgan analgesic product sell principally europe month inventory hand internationally direct customer september june level inventory hand primarily order pattern pharmacist france change distribution model thecount product greece fervex cold flu product month inventory hand direct customer compare month inventory hand june level inventory hand primarily russia france support product seasonality donormyl prescription sleep aid month inventory hand direct customer compare month inventory hand june level inventory hand primarily russia lower expect demand competitor price generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process business outside significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely direct customer product level inventory ultimate patientconsumer demand outmovement datum exist available develop variety methodology estimate datum include factor historical sale direct customer thirdparty market research datum relate prescription trend endus demand accordingly rely variety method estimate direct customer product level inventory calculate month hand factor affect estimate include generic competition seasonality product direct customer purchase light price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior file annual report disclose product level inventory excess month hand expect demand subject minimis exception quarterly report form expense change dollar million cost product sell marketing sell administrative research development incomeexpense total expense change excess cost product sell cost product sell include material cost internal labor overhead own manufacturing site thirdparty processing cost supply chain cost settlement foreign currency forward contract hedge forecast intercompany inventory purchase transaction essentially cost manage global manufacturing supply organization cost product sell include royalty profit sharing attribute license product alliance amortization acquire develop technology cost business combination milestone payment occur regulatory approval cost product sell vary period result product mix volume particularly result royalty profit sharing expense connection alliance change foreign currency price inflation cost attribute rationalization manufacturing site result accelerated depreciation impairment charge strand cost cost product sell remain relatively flat high profit share royalty alliance primarily eliquis offset favorable foreign exchange cost product sell decrease primarily diabetes business divestiture billion partially offset high eliquis profit sharing million accelerate depreciation certain manufacturing facility marketing sell administrative marketing selling administrative expense include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost advertising product promotion expense attribute product manufacturing cost research development expense expense manage regional commercialization organization global corporate organization finance legal information technology human resource certain expense share alliance partner base contractual agreement marketing sell administrative expense remain relatively flat increase salesrelated activity support eliquis opdivo hepatitis franchise offset favorable foreign exchange million additional expense relate brand prescription drug fee result change irs guideline marketing sell administrative expense remain relatively flat increase salesrelated activity support eliquis yervoy opdivo hepatitis franchise high variable employee compensation additional brand prescription drug fee offset low expense follow diabetes business divestiture million july irs issue final rule regulation brand prescription drug fee annual nontaxdeductible fee payable federal government affordable care act base allocation company market share brand prescription drug sell certain government program prior year final rule accelerate bms industry participant expense recognition criterion fee obligation year fee pay year market share allocate fee determine result additional year expense recognize quarter include million marketing selling administrative expense million expense final rule regulation change time annual fee pay research development research development activity include discovery research preclinical clinical development drug formulation clinical trial medical support market product expense include salary benefit cost thirdparty grant fee pay clinical research organization supply upfront contingent milestone payment license asset acquisition investigational compound iprd impairment charge proportionate allocation enterprisewide cost allocation include facility information technology employee stock compensation cost appropriate cost certain expense share alliance partner base contractual agreement expense vary period number reason include time upfront contingent milestone payment license asset acquisition iprd impairment charge research development expense increase high charge result investigational compound acquisition include million flexus million cardioxyl upfront payment new alliance license agreement include million prime increase investment accelerate expand opdivo development program partially offset low iprd impairment charge include million lpa antagonist favorable foreign exchange research development expense increase million iprd impairment charge include million peginterferon lambda high variable employee compensation clinical development cost million charge acquisition ipierian inc ipierian upfront contingent milestone payment alliance license agreement million refer item financial statementsnote alliance note acquisition divestiture note goodwill intangible asset information incomeexpense year end december dollar million interest expense investment income provision restructure litigation settlement equity net income affiliate outlicense intangible asset impairment gain sale business product line assets alliance license income pension charge loss debt redemption incomeexpense litigation settlement include additional charge million contractual dispute relate license subsequent company earning release fourth quarter gain sale business product line asset primarily result sale ixempra business mount vernon indiana manufacturing facility certain mature overthecounter product business transfer erbitux north america diabete business divestiture refer item financial statementsnote alliance note acquisition divestiture details alliance licensing income include royalty transitional service fee result diabete business divestiture income million result change fair value write option liability attribute reckitt benckiser group plc reckitt alliance refer item financial statementsnote alliance discussion pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan charge include acceleration portion unrecognize actuarial loss likely occur future additional pension settlement charge million recognize follow purchase group annuity contract prudential insurance company america december refer item financial statementsnote pension postretirement postemployment liability detail loss debt redemption result early redemption euro note tender offer certain debt security refer item financial statementsnote financial instrument fair value measurement detail income taxis dollar million earning income taxis provision income taxis effective tax rate historically effective income tax rate low statutory rate decision indefinitely reinvest earning certain manufacturing operation switzerland ireland puerto rico bms operate favorable tax grant puerto rico schedule expire prior tax impact attribute research development charge divestiture transaction specify item include additional transfer pricing reserve increase effective tax rate reduce effective tax rate tax benefit attribute research development charge result acquisition flexus cardioxyl ipierian minimal income taxis attribute diabetes business divestiture gain capital loss deduction sale amylin share tax basis difference result primarily allocate goodwill amylin defer taxis earning mix high low tax jurisdiction period retroactive reinstatement research development credit legislation impact effective tax rate refer item financial statementsnote income taxis information nongaap financial measure nongaap financial measure include nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item significant andor unusual nature evaluate individual basis similar charge gain item recognize prior period reasonably possible reoccur future period nongaap information intend portray result baseline performance include discovery development licensing manufacturing marketing distribution sale pharmaceutical product global basis enhance investor overall understanding past financial performance prospect future example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap specify item follow year end december dollar millions accelerate depreciation asset impairment shutdown cost amortization acquire amylin intangible asset amortization amylin alliance proceed amortization amylin inventory adjustment cost product sell additional year brand prescription drug fee process standardization implementation cost marketing sell administrative license asset acquisition charge iprd impairment research development provision restructure gain sale business product line asset pension charge acquisition alliance relate itemsa litigation settlement outlicense intangible asset impairment loss debt redemption upfront milestone licensing receipt incomeexpense increase pretax income income tax item specify tax chargeb income taxis increase net earning include million additional year brand prescription drug fee quarter specify tax charge relate transfer pricing matter reconciliations gaap nongaap follow year end december dollar million share datum net earning attributable bms diluted eps calculation gaap specify item net earning attributable bms diluted eps calculation nongaap average common share outstanding dilute diluted eps attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap financial position liquidity capital resource net cash position follow dollar million cash cash equivalent marketable security current marketable security noncurrent total cash cash equivalent marketable security shortterm borrowing longterm debt net cash position cash cash equivalent marketable security hold approximately billion december remain billion hold primarily lowtax jurisdiction attributable earning expected indefinitely reinveste offshore cash repatriation subject restriction certain jurisdiction subject withholding additional income taxis believe exist cash cash equivalent marketable security cash generate operation issuance commercial paper sufficient satisfy normal cash requirement year include dividend capital expenditure milestone payment work capital management continuously evaluate company capital structure ensure company finance efficiently include potential opportunity repurchase certain debt security terminate certain interest rate swap contract prior maturity access capital market subject market condition example issue senior unsecured note register public offering generating proceed billion redeemedrepurchase certain note nearly billion refer item financial statementsnote financial instrument fair value measurement detail issue commercial paper meet nearterm domestic liquidity requirement average commercial paper outstanding million weightedaverage interest rate maximum month end commercial paper outstanding million outstanding borrowing december dividend payment billion billion billion dividend decision quarterly basis board director capital expenditure approximately million approximately million expect approximately billion billion high spending expect result expand biologic manufacturing capability facilityrelate activity example construct new largescale biologic manufacturing facility ireland produce multiple therapy grow biologic portfolio complete marketable security portfolio subject change fair value result interest rate fluctuation market factor impact result operation investment policy place limit investment time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard refer item financial statement note financial instrument fair value measurement detail separate billion fiveyear revolve credit facility maintain syndicate lender facility provide customary term condition financial covenant extendable anniversary date consent lender borrowing outstanding revolve credit facility december additional regulation pass future negatively impact result operation operate cash flow liquidity financial flexibility continue monitor potential impact economic condition certain european country relate impact prescription trend pricing discount creditworthiness customer ability collect outstanding receivable direct customer currently believe economic condition material impact liquidity cash flow financial flexibility exposure certain european governmentbacke entity high risk default governmentbacke entity monitor economic factor include credit rating creditdefault swap rate debttogross domestic product ratio addition entity specific factor manage exposure factor certain receivables include receivables italy portugal spain circumstance permit factoring receivables country million million million factoring receivables japan million million factoring agreement allow recourse event uncollectibility retain interest underlie asset sell credit rating bms longterm shortterm credit rating assign moody investor service prime respectively longterm credit outlook revise negative stable april bms longterm shortterm credit rating assign standard poor respectively stable long term credit outlook bms longterm shortterm credit rating assign fitch respectively stable longterm credit outlook longterm rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating reflect agency opinion good extremely strong capacity timely repayment credit rating downgrade affect interest rate debt incur fair market value exist debt ability access capital market generally cash flow follow discussion cash flow activity dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt cash disbursement activity invest activity financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee pension contribution tax payment ordinary course business billion decrease cash provide operating activity primarily attributable timing payment alliance partner approximately million particularly active product ingredient supply medicaid rebate abilify high upfront payment new alliance licensing agreement approximately million timing customer collection result primarily high net product sale include extended payment term certain new product factor approximately million partially offset time cash collection payment ordinary course business include item change inventory level particularly relate abilify million decrease cash provide operating activity primarily attributable low upfront contingent alliance proceed approximately million reckitt alliance proceed million additional net work capital requirement approximately million partially offset time cash collection payment ordinary course business include item low pension contribution restructure annual bonus payment invest activity cash requirement invest activity include cash business asset acquisition manufacturing facilityrelate capital expenditure purchase marketable security maturity great day reduce proceed business divestiture sale maturity marketable security billion decrease cash provide investing activity primarily attributable low proceed result diabetes business divestiture billion million billion cash acquire flexus million cardioxyl million high capital expenditure approximately million partially offset low net purchase marketable security billion cash acquire ipierian million billion decrease cash investing activity primarily attributable proceed billion allocate diabetes business divestiture partially offset high net purchase marketable security approximately billion cash acquire ipierian million financing activity cash requirement financing activity include cash pay dividend repurchase common stock repay longterm debt borrowing reduce proceed exercise stock option issuance longterm debt borrowing million increase cash financing activity primarily attributable low shortterm borrowing approximately million consist primarily change bank overdraft billion increase cash financing activity primarily attributable low net borrowing longterm debt transaction billion million repayment million net borrowing low proceed stock option exercise million million include excess tax benefit partially offset low cash repurchase common stock million contractual obligation payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb longterm liability total include estimate future interest payment periodic cash settlement derivative include shortterm uncertain tax benefit uncertainty timing resolution addition commit aggregate billion potential future research development milestone payment party license asset acquisition development program include earlystage milestone billion milestone achieve phase iii clinical trial late stage milestone billion milestone achieve post phase iii clinical trial payment generally payable achievement certain developmental regulatory milestone specific timing predict agreement provide salesbased milestone aggregate billion obligate pay alliance partner achievement certain sale level addition royalty certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation refer item financial statementsnote alliance information alliance discussion contractual obligation refer item financial statementsnote income taxis note financial instrument fair value measurement note pension postretirement postemployment liability note lease sec consent order fcpa settlement previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec establish business risk disclosure group retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain inventory management agreement imas pharmaceutical wholesaler account nearly gross revenue current term ima wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent addition previously disclose october company reach civil settlement sec allege foreign corrupt practice act fcpa violation company agree approximately million disgorgement penalty interest settlement company agree year selfmonitoring period report government maintain procedure ensure compliance recently issue accounting standard recently issue accounting standard refer item financial statementsnote accounting policiesrecently issue accounting standard critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly impact financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain uncertainty actual result vary estimate accounting policy discuss audit committee board director revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally shipment certain market occur delivery product customer defer approximately million invoice daklinza early access program france portion recognize revenue final pricing obtain france revenue reduce grosstonet sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience alliance arrangement involve delivery element undelivered element evaluate qualify separate unit accounting consideration fix determinable allocate undelivered element recognize related good service deliver limited consideration contingent future deliverable consideration associate contingent milestone royalty allocate underlie element amount determined payable bms grosstonet adjustment follow category grosstonet adjustment involve significant estimate judgment information obtain external source refer total revenue discussion analysis significant category grosstonet sale adjustment chargeback cash discount business participate program government entity significant department defense department veteran affair party include cover entity drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag certain country cash discount offer incentive prompt payment generally approximate sale price account receivable reduce estimate unprocessed cash discount typically month time lag medicaid medicare rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual medicaid rebate extend drug manage medicaid plan estimate unpaid unbilled rebate present liability rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit pay point service discount center medicare medicaid services medicare beneficiarie coverage gap donut hole estimate unpaid unbilled rebate discount present liability sale return product typically eligible return month prior month product expiration accordance policy estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product low demand follow loss exclusivity estimate product return present liability estimate return new product determine consider historical sale return experience similar product product line similar therapeutic category defer recognition revenue right return expire sufficient historical experience estimate sale return develop limited circumstance typically occur new product extension exist line product historical experience product similar therapeutic category lack estimate level inventory distribution channel project demand consider estimate sale return new product rebate discount adjustment grosstonet sale adjustment include program base applicable law regulation individual nonus country rebate offer manage healthcare organization less extent nonus program include different pricing scheme cost cap volume discount outcomebase pricing scheme pricing clawback base sale individual company aggregation company participate specific market estimate unpaid unbilled rebate discount present liability use information external source information external source estimate grosstonet adjustment estimate inventory wholesaler base project prescription demandbase sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information retirement benefit account pension postretirement benefit plan require actuarial valuation base significant assumption discount rate expect longterm rate return plan asset consultation actuary significant assumption salary growth retirement turnover healthcare trend mortality rate evaluate select base expectation actual experience remeasurement date pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor yield high quality corporate bond coincide cash flow plan estimate payout determine discount rate citigroup pension discount curve plan plan pension expense determine weightedaverage discount rate present value benefit obligation december pension plan determine discount rate discount rate determine plan pension expense reduce additional expense increase approximately million assumed discount rate determine pension plan project benefit obligation december reduce additional project benefit obligation increase approximately billion new mortality table mortality improvement scale issue society actuary reflect long life expectancie previous table new table measure pension postretirement obligation begin september result increase obligation approximately million revise mortality rate expect materially impact pension expense future period expect longterm rate return plan asset estimate consider expect return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit refer item financial statementsnote pension postretirement postemployment liabilitie business combination divestiture goodwill intangible asset acquire business combination licensing transaction billion represent total asset december accounting transaction business combination divestiture significantly different asset acquisition divestiture example acquire iprd capitalize business combination expense asset acquisition fair value contingent consideration goodwill recognize business combination transaction likewise portion report unit constitute business divest goodwill associate business include carry value business determine gain loss derecognition goodwill occur asset disposition result important determine business asset group asset acquire divest business define asc business combination integrate set input process capable generate output ability provide return investor owner typical input include longlive asset include intangible asset right use longlived asset intellectual property ability obtain access require resource typical process include strategic operational resource management process typically document evident organized workforce consider factor determine business acquire divest compound development phase commercial product involve example evaluate acquisition cardioxyl flexus ipierian conclude significant process transfer transaction account asset acquisition result amount allocate lead investigational compound expense capitalize addition contingent consideration potential development regulatory approval salesbase milestone salesbase royalty include purchase price refer item financial statementsnote acquisition divestiture discussion acquisition similarly evaluate divestiture erbitux ixempra business comprise alliance medicine company valeant pharmaceuticals international inc diabetes business astrazeneca plc astrazeneca conclude necessary input process transfer consequently transaction account sale business result allocation goodwill million million carrying value business determine gain sale contingent proceed related divestiture recognize realize valuation process require certain multiple element arrangement include determination judgmental complex matter discuss example bms purchase warrant give bms exclusive right acquire promedior require determination well estimate selling price separate element identify transaction warrant clinical development service similarly divestiture diabete business astrazeneca require determination well estimate selling price element include business supply development agreement include appropriate markup estimate fair value manufacture facility refer item financial statementsnote alliance discussion transaction impairment intangible asset include iprd intangible asset billion december include license million develop technology right million capitalize software million iprd million intangible asset assess impairment current fact circumstance warrant review iprd assess annually intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include competition early expect loss exclusivity pricing pressure adverse regulatory change clinical trial result delay failure obtain regulatory approval additional development cost inability achieve expect synergy high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation consider high risk nature research development industry success rate bring developmental compound market iprd impairment charge likely occur future period recognize million charge bms phase development treatment idiopathic pulmonary fibrosis million include million charge peginterferon lambda phase iii development treatment hcv discussion iprd impairment refer item financial statementsnote goodwill intangible asset property plant equipment property plant equipment test impairment current fact circumstance warrant review additionally longlive asset periodically review determine change fact circumstance result change estimate useful life asset possibly result acceleration depreciation circumstance exist estimate undiscounted future cash flow generate asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use accelerate depreciation relate charge certain manufacturing facility million million million contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency refer item financial statementsnote accounting policiescontingencie note income taxis note legal proceeding contingency income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion december net valuation allowance billion billion december net valuation allowance billion defer tax asset relate federal net operating loss carryforward million federal tax credit carryforward million recognize december net operating loss carryforward expire vary amount begin federal tax credit carryforward expire vary amount begin realization carryforward dependent generating sufficient domesticsource taxable income prior expiration million valuation allowance establish item december assured believe likely defer tax asset value realize taxis provide undistributed earning foreign subsidiary expect reinveste indefinitely offshore prior mead johnson nutrition company mead johnson splitoff follow transaction occur internal spinoff mead johnson share own conversion mead johnson class share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement include certain taxis relate business prior completion ipo create restructure facilitate ipo mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know example additional reserve million establish certain transfer pricing matter relate period discussion income taxis refer item financial statementsnote accounting policiesincome taxis note income taxis product pipeline development program manage portfolio basis early discovery latestage development continually evaluate portfolio ensure appropriate balance earlystage latestage program support future growth program phase iii development consider significant program constitute latestage development pipeline development program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation spend program represent approximately annual expense individual investigational compound market product represent expense year opdivo latestage development program potentially impact revenue earning year expect latestage development program market follow development market product late stage pipeline opdivo fully human monoclonal antibody bind nkt cell approve continue investigate anticancer treatment opdivo alliance ono unresectable inoperable metastatic advanced melanoma january company announce randomize phase iii study evaluate opdivo versus investigator choice patient recurrent metastatic platinumrefractory squamous cell carcinoma head neck stop early assessment conduct independent datum monitor committee dmc conclude study meet primary endpoint demonstrate superior overall survival patient receive opdivo compare control arm january company announce fda approve opdivo combination yervoy treatment patient braf wildtype braf mutation positive unresectable metastatic melanoma approval expand original indication opdivoyervoy regimen treatment patient braf wildtype unresectable metastatic melanoma include patient regardless braf mutational status base datum phase iii checkmate trial evaluate progressionfree survival overall survival coprimary endpoint indication approve accelerate approval base progressionfree survival january company announce fda expand use opdivo single agent include previously untreated braf mutation positive advanced melanoma patient use opdivo single agent patient braf mutation positive unresectable metastatic melanoma approve accelerate approval base progressionfree survival november company announce fda approve opdivo single agent treatment previously untreated patient braf wildtype unresectable metastatic melanoma november company announce result multiple clinical trial checkmate study evaluate opdivo single agent versus dacarbazine patient previously untreate braf wildtype unresectable metastatic melanoma opdivo continue demonstrate superior overall survival versus dacarbazine patient alive year compare patient treat dacarbazine safety profile opdivo consistent prior study study study evaluate opdivo combination yervoy patient unresectable metastatic melanoma proof concept opdivoyervoy regimen approval base datum long follow regiman phase cohort show threeyear overall survival rate phase dosing cohort frequency treatmentrelate adverse event study similar cohort consistent phase iii trial combination therapy september fda approve opdivo combination yervoy treatment patient braf wildtype unresectable metastatic melanoma announcement mark fda approval regimen immunooncology agent cancer indication approve accelerate approval base tumor response rate durability response july european medicines agency ema validate company type variation application seek extend use opdivo combination yervoy treatment advance unresectable metastatic melanoma adult application base datum phase iii checkmate study phase checkmate study phase study validation application confirm submission complete start ema centralized review process june company announce european commission approve opdivo treatment firstline previously treat unresectable metastatic melanoma patient regardless braf status approval allow marketing opdivo member states opdivo immune checkpoint inhibitor receive accelerate assessment europe approval give inhibitor cancer company announce positive result phase iii trial checkmate evaluate opdivoyervoy regimen opdivo monotherapy yervoy monotherapy patient previously untreate advanced melanoma opdivoyervoy regimen opdivo monotherapy demonstrate superiority yervoy current standard care coprimary endpoint progressionfree survival pfs median pfs months opdivoyervoy regimen month opdivo monotherapy month yervoy monotherapy opdivoyervoy regimen demonstrate reduction risk disease progression yervoy hazard ratio opdivo monotherapy demonstrate risk reduction versus yervoy monotherapy hazard ratio hazard ratio exploratory endpoint compare opdivoyervoy pfs opdivo pfs safety profile consistent previouslyreported study evaluate opdivoyervoy regimen treatmentrelate adverse event rate opdivoyervoy regimen compare opdivo monotherapy yervoy monotherapy select treatmentrelated adverse event resolve establish management guideline trial ongoing patient continue follow overall survival coprimary endpoint april company announce positive result phase trial checkmate evaluate opdivoyervoy regimen versus yervoy patient previously untreate advanced melanoma patient braf wildtype mutation status treat opdivoyervoy regiman experience high objective response rate orr primary study endpoint compare patient administer yervoy monotherapy complete response report patient braf wildtype mutation status administer opdivoyervoy regimen patient receive yervoy monotherapy similar result observe braf mutationpositive patient nsclc december company ono announce ono receive manufacturing marketing approval opdivo japan treatment patient unresectable advanced recurrent nsclc november company announce approve reconciliation indication nivolumab opdivo european marketing authorization application maa compliance regulation bms previously submit separate maas ema opdivo treatment unresectable metastatic melanoma adult nivolumab bms treatment locally advanced metastatic nsclc prior chemotherapy application reconcile indication submit opdivo brand follow approval indication early year company voluntarily withdraw marketing authorization nivolumab bms brand withdrawal impact nsclc patient take nivolumab opdivo approve treatment nsclc melanoma october company announce fda approve opdivo treatment previously treat patient nsq nsclc regardless pdl expression expand current indication opdivo patient previously treat nsclc september company announce long term month survival datum checkmate openlabel randomize phase iii study evaluate opdivo versus docetaxel previously treat patient advance nsq nsclc opdivo continue demonstrate superior overall survival studys primary endpoint estimate patient alive month versus docetaxel base minimum followup month opdivo continue demonstrate reduction risk death hazard ratio study grade treatmentrelate adverse event report patient treat opdivo versus docetaxel arm september company announce update result opdivoyervoy arm checkmate multiarm phase trial evaluate opdivo patient chemotherapynave advanced nsclc study opdivo administer monotherapy combination agent include yervoy different dose schedule result cohort checkmate previouslyunreporte update result include finding administration new dosing schedule opdivoyervoy result confirmed objective response rate range depend administer regimen median duration response reach arm median followup month month median progressionfree survival pfs range month month type treatmentrelate adverse event report cohort checkmate consistent previouslyreported opdivoyervoy cohort trial new dosing schedule study result toxicity previouslyreported dose schedule characterize low frequency treatmentrelate adverse event lead discontinuation treatmentrelate death september company announce long term survival safety datum checkmate pivotal trial evaluate opdivo previously treat nsclc show sustained survival benefit study trial opdivo show estimate month overall survival rate checkmate checkmate survival benefit independent pdl expression safety profile opdivo consistent previouslyreported trial checkmate favorable compare docetaxel july ema validate company type variation application seek extend use opdivo monotherapy nsq nsclc base datum phase iii checkmate study july company announce approve nivolumab bms treatment locally advanced metastatic nsclc prior chemotherapy approval mark major treatment advance nsclc decade nivolumab immune checkpoint inhibitor demonstrate overall survival previouslytreate metastatic nsclc company announce result checkmate phase iii openlabel randomize study evaluate opdivo versus docetaxel previously treat patient advance nsclc year opdivo demonstrate overall survival rate versus docetaxel median overall survival month versus month respectively opdivo reduce risk death base hazard ratio safety profile opdivo checkmate consistent prior study favorable versus docetaxel company announce opdivo inhibitor demonstrate superior overall survival versus standard care docetaxel openlabel randomize phase iii study checkmate evaluate previouslytreated patient advance nsq nsclc reduction risk progression death primary study endpoint report opdivo versus docetaxel base hazard ratio opdivo associate double overall median survival continuum pdl expression start level expression trial safety profile opdivo checkmate favorable versus docetaxel grade treatmentrelate adverse event report patient treat opdivo versus docetaxel arm april company announce checkmate stop early assessment conduct independent dmc conclude study meet primary endpoint march company announce fda approve opdivo treatment patient advance nsclc progression platinumbase chemotherapy opdivo therapy demonstrate overall survival previously treat advanced nsclc opdivo demonstrate significantly superior overall survival docetaxel reduction risk death hazard ratio prespecifie interim analysis phase iii clinical trial median overall survival month opdivo arm months docetaxel arm indications november company announce fda approve opdivo treatment patient advance rcc receive prior anti angiogenic therapy november company announce ema validate type variation application seeks extend current indication opdivo include treatment adult patient advance rcc prior therapy validation application confirm submission complete begin emas centralized review process september company announce result checkmate phase iii study compare opdivo everolimus advanced rcc prior anti angiogenic treatment show significant overall survival benefit opdivo trial opdivo demonstrate median overall survival benefit month compare month everolimus clinical benefit opdivo observe regardless level pdl expression safety profile show checkmate consistent previously report opdivo trial july company announce checkmate stop early assessment independent dmc conclude study meet primary endpoint company announce result interim analysis phase iii doserange trial evaluate safety antitumor activity opdivo previouslytreate patient hepatocellular carcinoma hcc advanced liver cancer initial finding demonstrate estimate survival rate evaluable patient month result safety profile opdivo generally consistent previously report opdivo tumor type empliciti humanize monoclonal antibody treatment multiple myeloma empliciti alliance abbvie inc abbvie january company abbvie announce committee medicinal product human use chmp ema adopt positive opinion recommend empliciti grant approval treatment multiple myeloma combination therapy revlimid dexamethasone patient receive prior therapy application review authority approve medicine december company abbvie announce extended followup datum prespecifie interim overall survival analysis empliciti combination revlimid dexamethasone erd patient relapse refractory multiple myeloma eloquent followup datum demonstrate empliciti combination improvement progressionfree survival hazard ratio versus result consistent improvement pfs observe time primary analysis november company abbvie announce fda approve empliciti treatment multiple myeloma combination therapy revlimid dexamethasone patient receive prior therapy june company abbvie announce result interim analysis phase iii randomized openlabel eloquent trial trial evaluate empliciti combination lenalidomide dexamethasone eld versus lenalidomide dexamethasone treatment relapse refractory multiple myeloma study meet coprimary endpoint demonstrate superior pfs orr eld arm demonstrate reduction risk disease progression death compare arm pfs rate eld arm versus arm versus year versus year respectively significant orr observe eld arm compare arm odd ratio safety profile consistent previouslyreported study minimal incremental adverse event addition empliciti lenalidomide dexamethasone sprycel oral inhibitor multiple tyrosine kinase indicate firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib mesylate sprycel alliance otsuka pharmaceutical ltd otsuka august company otsuka announce fda approve update sprycel product labeling labeling include fiveyear efficacy safety datum adult patient newly diagnose philadelphia chromosomepositive cml sevenyear datum cml patient resistant intolerant prior therapy include gleevec imatinib mesylate yervoy monoclonal antibody treatment patient unresectable metastatic melanoma october company announce fda approve yervoy adjuvant treatment patient cutaneous melanoma pathologic involvement regional lymph nodes undergo complete resection include total lymphadenectomy october company announce yervoy phase iii trial study subject stage ivrecurrent nsclc compare efficacy yervoy combination paclitaxel carboplatin versus placebo versus paclitaxel carboplatin meet primary endpoint overall survival yervoy treatment arm discontinue new safety concern yervoy identify study company complete evaluation datum work investigator future publication result july company announce yervoy phase iii trial study metastatic castration resistant prostate cancer study newly diagnose extensivestage disease small cell lung cancer meet primary endpoint overall survival versus standard care discontinue new safety concern yervoy identify study company complete evaluation datum work investigator future publication result july japanese ministry health labour welfare approve yervoy second line treatment unresectable malignant melanoma hepatitis portfolio daklinza dcv nsa replication complex inhibitor sunvepra asv protease inhibitor beclabuvir bcv nsb non nucleoside polymerase inhibitor development january company announce fda approve daklinza combination sofosbuvir ribavirin genotype expand label include datum additional challengingtotreat patient population chronic hcv patient hiv coinfection advance cirrhosis postliver transplant recurrence hcv daklinza plus sofosbuvir regimen available treatment chronic hcv genotype currently week oncedaily alloral treatment option patient sustain virologic response svr rate reduce genotype patient cirrhosis receive daklinza sofosbuvir week ribavirin sofosbuvir product gilead sciences inc gilead january company announce approve daklinza treatment chronic hcv new patient population expand label allow use daklinza combination sofosbuvir ribavirin depend indication hcv genotype hcv patient decompensate cirrhosis hiv coinfection postliver transplant recurrence hcv member states november company announce datum phase iii ally trial investigate regimen daklinza combination sofosbuvir ribavirin genotype hcv patient advance fibrosis cirrhosis treatment duration week patient population difficult treat svr rate cure prove hard achieve result patient advanced fibrosis cohort achieve svr week arm study svr rate patient cirrhosis week arm respectively october company announce national institute health care excellence nice recommend daklinza england wale treatment adult patient chronic hcv specifically nice recommend daklinza treat certain patient hcv genotype approximately people think chronic hcv roughly patient estimate genotype difficulttotreat aggressive form chronic hcv september company announce approve update label daklinza treatment genotype chronic hcv update allow use daklinza combination sofosbuvir week patient cirrhosis member state mark time patient genotype hcv oncedaily alloral treatment regimen short duration july company announce fda approve daklinza use sofosbuvir treatment patient chronic hcv genotype approval mark time patient chronic hcv genotype week oncedaily alloral treatment option svr rate reduce hcv genotype infect patient cirrhosis receive regiman july company announce plan seek regulatory approval new drug application hcv tripleregimen trio dcv asv bcv united states europe company announce fda amend previously grant breakthrough therapy designation investigational daclatasvir sofosbuvir combination use hcv patient update designation reflects recently present datum hcv genotype patient advance cirrhosis childpugh class develop genotype hcv recurrence postliver transplant april company announce primary endpoint successfully meet ally phase iii clinical trial evaluate week combination daclatasvir sofosbuvir oncedaily ribavirin treatment patient chronic hcv advanced cirrhosis postliver transplant recurrence hcv february company announce result ally phase iii clinical trial evaluate investigational oncedaily combination daclatasvir sofosbuvir treatment patient chronic hcv coinfecte hiv patient population historically challenge treat large potential drugdrug interaction therapy regimen treat infection ally patient treat week treatmentnave experience achieve cure svr week treatment study meet primary endpoint treatmentnave genotype patient achieve svr treatment daclatasvir combination sofosbuvir study show high svr rate discontinuation adverse event adverse event relate study medication treatment phase february fda notify company intention rescind breakthrough therapy designation certain genotype hcv regimen relate daclatasvir investigational bms therapy impact current submissionresubmission timetable nda daclatasvir combination antiviral agent treatment hcv reyataz franchise protease inhibitor treatment hiv include reyataz include combination therapy evotaz atazanavir cobicistat evotaz license agreement gilead july company announce approve evotaz treatment hiv infect adult know mutation associate resistance atazanavir evotaz oncedaily single tablet drug regiman combine reyataz tybost tybost product gilead june fda grant pediatric exclusivity reyataz provide additional month period exclusivity january company announce fda approve evotaz treatment hiv infection adult oncedaily single tablet drug regiman combine reyataz tybost orencia fusion protein indicate adult patient moderate severe active indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular juvenile idiopathic arthritis june company announce datum orencia phase iiib avert ample trial trial include early moderate severe patient active disease avert trial datum suggest potentially fast onset clinical response great drugfree clinical remission early use patient take orencia plus methotrexate patient take methotrexate exploratory data patient high anticitrullinate protein antibody level baseline ample trial suggest well response orencia adalimumab adalimumab product abbvie april ema approve clickject prefille pen new autoinjector delivery device orencia use adult patient moderate severe active combination methotrexate inadequate diseasemodifying antirheumatic drug response eliquis oral factor inhibitor target stroke prevention nvaf prevention treatment vte disorder eliquis alliance pfizer inc pfizer december company pfizer announce result posthoc early time course subanalysis phase iii amplify trial subanalysis demonstrate eliquis comparable conventional therapy subcutaneous enoxaparin overlap follow oral warfarin doseadjuste international normalize ratio recurrent vte vterelate death significantly major bleed day start treatment result subanalyse consistent overall result eliquis phase iii amplify trial september company pfizer announce patient enrol phase clinical trial augustus evaluate safety eliquis versus warfarin vitamin antagonist patient nvaf recent acute coronary syndrome undergo percutaneous coronary intervention know stent special note forwardlooke statement annual report include document incorporate reference write oral statement time time contain certain forwardlooking statement meaning section security act section securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year include important factor cautionary statement include annual report particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date undertake obligation release publicly revision forwardlooke statement result new information future event item quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen chinese renminbi canadian dollar south korean foreign currency forward contract manage risk primarily arise certain intercompany purchase transaction designate foreign currency cash flow hedge appropriate addition expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset exposure designate hedge estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million december reduce earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate designate hedge net investment effective portion foreign exchange gain loss hedge include foreign currency translation component accumulate comprehensive incomeloss net investment decrease equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information refer item financial statementsnote financial instrument fair value measurement interest rate risk use fixedtofloate interest rate swap contract designate fair value hedge forward start interest rate swap contract designate cash flow hedge interest rate risk management strategy contract intend provide appropriate balance fix float rate debt forward start swap contract manage interest rate future debt issuance estimate increase basis point shortterm longterm interest rate decrease fair value interest rate swap contract million decrease basis point shortterm longterm interest rate decrease fair value forward start interest rate swap contract million reduce earning remain life contract estimate increase basis point longterm interest rate decrease fair value longterm debt million marketable security subject change fair value result interest rate fluctuation market factor policy inv institution meet high credit quality standard estimate increase basis point interest rate general decrease fair value debt security portfolio approximately million credit risk material certain european governmentbacke entity high risk default greece portugal italy spain monitor economic factor include credit rating creditdefault swap rate debttogross domestic product ratio entity specific factor historically exposure limited factoring receivables credit exposure europe increase future reduction factor arrangement ongoe sovereign debt crisis monitor investment counterpartie objective minimize concentration credit risk investment policy establishe limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk fair value derivative instrument contract positive expose credit risk counterparty fails perform fair value derivative instrument contract negative counterparty expose credit risk fail perform obligation collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information refer item financial statementsnote financial instrument fair value measurement item financial statement supplementary datum bristolmyer squibb company consolidate statement earning dollar million share datum year end december earning net product sale alliance revenue total revenue cost product sell marketing sell administrative research development incomeexpense total expense earning income taxis provision income taxis net earning net earning attributable noncontrolle interest net earning attributable bms earning common share basic diluted cash dividend declare common share consolidate statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive incomeloss net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolle interest comprehensive income attributable bms accompany note integral consolidated financial statement bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory defer income taxis prepaid expense asset heldforsale total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm borrowing account payable accrue expense defer income accrue rebate return income taxis payable dividend payable total current liability pension postretirement postemployment liability defer income income taxis payable liability longterm debt total liability commitment contingency note equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity net earning attributable noncontrolle interest depreciation amortization net defer income taxis stockbase compensation impairment charge pension settlement amortization adjustment change operate asset liability receivable inventory account payable deferred income income taxis payable net cash provide operating activity cash flow invest activity sale maturity marketable security purchase marketable security capital expenditure divestiture proceed acquisition payment net cash provide byused investing activity cash flow financing activity shortterm borrowing net issuance longterm debt repayment longterm debt interest rate swap contract termination issuance common stock repurchase common stock dividend net cash financing activity effect exchange rate cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement note accounting policy recently issue accounting standard basis consolidation consolidate financial statement prepare conformity united states generally accept accounting principle gaap include account bristolmyer squibb company control majorityowned subsidiary certain variable interest entity refer bristol myers squibb bms company intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity consolidate bms power direct activity variable interest entity significantly impact economic performance obligation absorb loss right receive benefit potentially significant entity use estimate preparation financial statement require use management estimate assumption significant assumption estimate determine fair value potential impairment intangible asset sale rebate return accrual legal contingency income taxis estimate selling price multiple element arrangement pension postretirement benefit actual result differ estimate result reclassification certain prior period amount reclassify conform current period presentation advertising product promotion cost previously present separately consolidate statement earning include marketing sell administrative expense revenue recognition revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally time shipment include supply commercial product alliance partner principal end customer sale certain revenue nonus business recognize date receipt customer alliance revenue relate abilify atripla recognize product sell end customer alliance partner royalty recognize thirdparty sale reliably measurable collectability reasonably assure refer note alliance detail alliance revenue reduce time recognition expect sale return discount rebate sale allowance base historical experience update change fact circumstance include impact applicable healthcare legislation revenue defer historical experience product similar therapeutic category right return long exist sufficient historical experience estimate sale return develop income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement cash cash equivalent cash cash equivalent include bank deposit time deposit commercial paper money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable security investment company marketable security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity investment own company account equity method accounting ability exercise significant influence maintain share net income loss equity investment include incomeexpense equity investment review impairment assess decline market value investment carry value temporary consider intent ability retain investment duration extent market value cost investee financial condition inventory valuation inventory state low average cost market property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture impairment longlive asset current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique level fair value input include discount value estimate future cash flow capitalize software eligible cost obtain internal use software capitalize amortize estimate useful life software business combination business acquire consolidate obtain control fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill business acquisition cost expense incur goodwill acquire inprocess research development intangible asset fair value intangible asset typically determine income method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success iprd finitelive intangible asset include license develop technology right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow goodwill tested annually impairment assess qualitative factor perform quantitative analysis determine likely fair value net asset carry amount example qualitative factor assess include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annual basis frequently event occur circumstance change indicate potential reduction fair value asset carry value carry value iprd determine exceed fair value impairment loss recognize difference finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize restructure restructuring charge recognize result action streamline operation rationalize manufacture facility estimate impact restructuring plan include future termination benefit exit cost require judgment actual result vary estimate contingency loss contingency legal proceeding claim occur wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incurred shipping handle cost shipping handling cost include marketing sell administrative expense million million million advertising product promotion cost advertising product promotion cost include marketing sell administrative expense million million million advertising product promotion cost expense incur foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize oci research development research development cost expense incur clinical study cost accrue service period specify contract adjust necessary base ongoing review level effort cost actually incur strategic alliance party provide licensing right develop manufacture market andor sell pharmaceutical product right own party research development recognize net reimbursement connection alliance agreement upfront contingent milestone payment asset acquisition investigational compound include research development expense cash flow upfront contingent milestone payment license investigational compound include operating activity asset business acquisition include investing activity divestiture proceed include investing activity royalty consideration receive subsequent relate sale asset business adjustment reflect operating activity include divestiture gain loss relate royalty research development asset acquisition charge gain loss debt redemption change fair value write option liability recently issue accounting standard january financial accounting standard board fasb issue amend guidance recognition measurement presentation disclosure financial instrument effective january early adoption permit new guidance require fair value adjustment equity security readily determinable fair value currently classify availableforsale report earning new guidance require qualitative impairment assessment equity investment readily determinable fair value require impairment charge earning assessment indicate impairment exist company assess potential impact new standard consolidated financial statement november fasb issue amend guidance presentation defer tax asset liability new guidance require defer tax asset liability classify noncurrent bm elect early adopt standard december prospectively refer note income taxis information april fasb issue amend guidance presentation debt issuance cost new guidance require debt issuance cost present reduction carrying value debt balance sheet consistent debt discount bm elect early adopt standard december adoption standard material impact consolidate financial statement refer note financial instrument fair value measurement information fasb issue new standard relate revenue recognition require entity recognize revenue expect entitle transfer promise good service customer new standard replace exist revenue recognition standard gaap effective july fasb decide delay effective date year january early adoption permit early new standard apply retrospectively prior reporting period present retrospectively cumulative effect change recognize date initial application retain earning company assess potential impact new standard financial reporting select transition method april fasb issue amend guidance use presentation discontinue operation entity consolidated financial statement new guidance restrict presentation discontinue operation business circumstance disposal business operation represent strategic shift major effect entity operation financial result guidance effective january note business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible discovery development manufacturing supply product regional commercial organization market distribute sell product business support global corporate staff function segment information consistent financial information regularly review chief executive officer purpose evaluate performance allocate resource set incentive compensation target planning forecast future period product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross revenue large pharmaceutical wholesaler percentage global gross revenue follow mckesson corporation amerisourcebergen corporation cardinal health inc select geographic area information follow revenue property plant equipment dollar millions united states europe rest world othera total revenue include royalty alliancerelate revenue product sell regional commercial organization product revenue follow year end december dollar million virology baraclude entecavir hepatitis franchise reyataz atazanavir sulfate franchise sustiva efavirenz franchise oncology empliciti elotuzumab erbitux cetuximab opdivo nivolumab sprycel dasatinib yervoy ipilimumab neuroscience abilify aripiprazole immunoscience orencia abatacept cardiovascular eliquis apixaban mature product total revenue composition total revenue follow year end december dollar million net product sale alliance revenues revenues total revenue note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage right obligation party global limited geographic region refer collaboration alliance partner alliance partner key product sustiva atripla empliciti erbitux opdivo sprycel yervoy abilify orencia eliquis product comprise diabetes alliance discuss certain mature brand include alliance arrangement payment alliance partner account present result operation consider specific nature payment underlie activity payment relate multiple alliance activity include transfer right separate individual unit account standalone value activity occur life arrangement situation arrangement consideration allocate activity right relative sell price basis multiple alliance activity right standalone value combine single unit account common activity bms alliance partner present result operation follow bms principal end customer sale product sale include net product sale bms alliance partner principal end customer sale bms contractual share thirdparty sale andor royalty income include alliance revenue sale commercial product consider bms ongoing major central operation refer revenue recognition include note accounting policy information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenue sale commercial product consider bms ongoing major central operation profit share royalty salesbase fee payable bms alliance partner include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development approval milestone payable bms alliance partner investigational compound commercial product defer amortize short contractual term period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present incomeexpense activity perform time relate sale commercial product bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation astrazeneca plc astrazeneca alliance pertain amylin product discussion specific astrazeneca alliance disclosure upfront contingent approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow amortization include cost product sell upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include research development expense royalty contingent consideration payable bms alliance partner relate divestiture business include income earn equity net income affiliate include incomeexpense payment bms alliance partner present cash flow operating activity describe select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative research development incomeexpense noncontrolle interest pretax select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliance bms enter certain licensing alliance agreement include option license acquire related asset upfront payment new agreement charge research development expense million prior period amount disclose research development expense upfront payment alliance partner revise include similar type payment specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election income statement classification amount attributable payment party pfizer bms pfizer inc pfizer party worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover bms pfizer fund development cost depend study profit loss share equally global basis certain country pfizer commercialize eliquis pay bms compensation base percentage net sale enter agreement coexclusive license right product grant pfizer exchange upfront payment potential milestone payment party assume certain obligation actively participate alliance actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal end customer product sale significant country europe canada australia china japan south korea bms transfer commercialization right pfizer certain small country order simplify operation transfer country bms supply product pfizer cost plus percentage net sale endcustomer company determine right transfer pfizer standalone value right sell separately bms party pfizer receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting upfront proceed subsequent contingent milestone proceed amortize life relate product bms receive million nonrefundable upfront milestone licensing payment relate eliquis december amortization eliquis defer income include income eliquis commercial product commencement alliance summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing cost reimbursement pfizer incomeexpense amortization defer income select alliance cash flow information defer income select alliance balance sheet information december dollar millions defer income gilead bms gilead sciences inc gilead joint venture canada europe develop commercialize atripla efavirenz emtricitabine tenofovir disoproxil fumarate combine sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead joint venture consolidate gilead party actively participate joint executive committee operating committee direct oversight activity joint venture joint venture purchase sustiva truvada active pharmaceutical ingredient api bulk form party complete finishing atripla joint venture gilead sell distribute atripla principal end customer product sale party long coordinate joint promotional activity alliance revenue recognize atripla include bulk efavirenz component atripla base relative ratio average respective net selling price truvada sustiva alliance revenue defer related alliance receivable recognize combined product sell thirdparty customer europe follow loss exclusivity sustiva effective january percentage atripla net sale europe recognize bms equal difference average net selling price atripla truvada alliance continue europe party terminate arrangement patent expiration occur atripla truvada sustiva agreement terminate gilead launch generic version sustiva bms launch generic version truvada event gilead terminate agreement loss exclusivity sustiva bms receive quarterly royalty payment month follow termination payment month follow termination equal atripla net sale multiply ratio difference average net selling price atripla truvada atripla average net selling price second year follow termination payment bms reduce respectively atripla net sale multiply price ratio describe bms continue supply sustiva cost plus markup joint venture threeyear period party elect terminate supply arrangement enter licensing agreement gilead develop commercialize fixeddose combination contain reyataz gileads cobicistat pharmacoenhance boost agent increase blood level certain human immunodeficiency virus hiv medicine potentially allow pill daily dose evotaz atazanavir cobicistat approve food drug administration fda january european commission july summarize financial information relate alliance follow year end december dollar million revenue gilead alliance alliance revenues equity net loss affiliate select alliance balance sheet information december dollar millions defer income otsuka bms worldwide commercialization agreement otsuka pharmaceutical ltd otsuka codevelop copromote abilify exclude certain asian country portion agreement expire april agreement expire european union countries june non country exclusive right sell abilify agreement expire later april loss exclusivity country party actively participate joint executive governance operate committee otsuka responsible provide sale force effort effective january bms responsible certain operating expense annual limit bms purchase api otsuka complete manufacture product subsequent sale thirdparty customer certain country otsuka assume responsibility provide funding sale force effort effective april bms provide certain service include distribution customer management pharmacovigilence bms principal end customer product sale exclusive distributor exclusive right sell abilify otsuka principal end customer product sale alliance revenue include bmss share total net sale thirdparty customer territory bmss contractual share net sale set forth table assessment bms expect annual contractual share complete quarterly reporting period adjust base report abilify net sale year end bms annual contractual share alliance revenue recognize interim period quarter exceed amount contract annual net sale bms share net sale billion billion billion billion billion billion billion billion billion excess billion bmss contractual share thirdparty net sale countrie alliance revenue recognize abilify ship risk reward ownership transfer thirdparty customer bms otsuka alliance sprycel japan oncology territory party copromote product february copromotion agreement otsuka terminate japan party actively participate governance committee bms control decision make bms responsible development manufacture product principal end customer product sale ixempra ixabepilone include alliance prior bms divestiture business fee pay otsuka base follow percentage combine annual net sale sprycel ixempra oncology territory include post divestiture ixempra sale net sale million million million million million million billion excess billion annual period otsuka contribute million certain commercial operational expense relate oncology product oncology territory cost excess million summarize financial information relate alliance follow year end december dollar million revenue otsuka alliance net product sale alliance revenuesa total revenue payment tofrom otsuka cost product sell oncology fee royalty cost product supply include amortization extension payment reduction alliance revenue million million lilly bms commercialization agreement eli lilly company lilly lilly subsidiary imclone codevelopment promotion erbitux canada japan party actively participate joint executive committee operating committee share responsibility research development resource infrastructure lilly manufacture bulk requirement erbitux facility filling finish perform party bms oversight responsibility bm exclusive distribution right north america responsible promotional effort north america lilly right copromote expense bms principal end customer product sale north america pay lilly distribution fee erbitux net sale north america plus share certain royalty pay lilly bmss right obligation respect commercialization erbitux north america expired september october bms transfer right erbitux north america lilly exchange salesbase royalty describe transfer right include limited commercialization manufacturing responsibility transaction account business divestiture result noncash charge million intangible asset directly relate business allocation goodwill bms receive royalty september include income earn royalty rate applicable north america erbitux net sale million million million million plus net sale excess amount respective year bms share right erbitux japan agreement lilly merck kgaa receive pretax profit merck kgaas net sale erbitux japan share equally lilly bm transfer cocommercialization right japan merck kgaa exchange sale base royalty include income earn march bms lilly terminate arrangement necitumumab imcf right return lilly discover imclone necitumumab fully human monoclonal antibody alliance bms lilly summarize financial information relate alliance follow year end december dollar millions revenue lilly alliance net product sale alliance revenue total revenue payment tofrom lilly cost product sell distribution fee royalty amortization intangible asset cost product supply incomeexpense royalty loss sale business select alliance balance sheet information december dollar million intangible asset nonrefundable upfront milestone licensing payment astrazeneca prior diabetes business divestiture discuss bms alliance astrazeneca consist worldwide codevelopment commercialization agreement cover onglyza relate combination product sell name farxiga relate combination product begin august bms acquisition amylin pharmaceuticals inc amylin amylin portfolio product include bydureon byetta symlin myalept certain asset own amylin include manufacturing facility locate west chester ohio coexclusive license right product product underlying agreement grant astrazeneca exchange upfront payment potential milestone payment party assume certain obligation actively participate alliance party actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal end customer product sale substantially country alliance agreement right transfer astrazeneca standalone value right sell separately bms party astrazeneca receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting result upfront proceed subsequent contingent milestone proceed amortize life relate product bms receive billion nonrefundable upfront payment astrazeneca consideration enter amylin alliance astrazeneca exercise option equal governance right certain key strategic financial decision amylin alliance pay bms million consideration payment account deferred income amortize base relative fair value predominant element include alliance estimate useful life intangible asset relate bydureon estimate useful life year byetta estimate useful life year symlin estimate life year myalept estimate useful life year amylin manufacture plant estimate useful life year amortization present reduction cost product sell alliance asset acquire shortly commencement alliance astrazeneca entitle share proceed sale asset amortization acquire amylin intangible asset manufacturing plant present cost product sell bms entitle reimbursement capital expenditure relate acquire amylin manufacturing facility bms astrazeneca share certain tax attribute relate amylin alliance prior termination alliance bms receive nonrefundable upfront milestone licensing payment million relate onglyza million relate farxiga amortization onglyza farxiga deferred income include income onglyza farxiga commercial product commencement alliance party share commercialization development expense equally profit loss february bms astrazeneca terminate alliance agreement bms sell astrazeneca substantially diabete business comprise alliance divestiture include share amylin result transfer ohio manufacturing facility intellectual property relate onglyza farxiga include bms interest outlicensing agreement onglyza japan purchase bmss manufacturing facility locate mount vernon indiana substantially employee dedicated diabetes business transfer astrazeneca bms astrazeneca enter agreement connection sale include supply agreement development agreement transitional service agreement agreement bms obligate supply certain product include active product ingredient onglyza farxiga perform ongoing development activity certain clinical trial program provide transitional service account financial service customer service distribution regulatory development information technology certain administrative service period order facilitate orderly transfer business operation annual cost attribute development agreement expect exceed approximately million consideration transaction include billion payment close contingent regulatory salesbase milestone payment billion include million relate approval milestone million relate salesbased milestone payable royalty payment base net sale payment million certain asset transfer astrazeneca astrazeneca pay bms require product supply price approximating product cost negotiate transitional service fee royalty rate net sale follow onglyza farxiga worldwide net sale million onglyza farxiga worldwide net sale million amylin product net sale stock asset purchase agreement contain multiple element deliver subsequent closing transaction include china diabete business transfer mount vernon indiana manufacturing facility transfer activity development supply agreement element determine standalone value result portion consideration receive closing allocate undelivered element relative selling price method determine well estimate selling price element remain consideration include calculation gain sale diabete business contingent milestone royalty payment similarly allocate underlie element amount determined payable bms amount allocate sale business immediately recognize result operation amount allocate element recognize result operation extent element deliver consideration billion account include royalty million contingent regulatory milestone payment relate approval farxiga japan approximately billion consideration allocate sale business remain million allocate undelivered element describe consideration include million earn royalty include million allocate element deliver gain sale diabete business million include million quarter result primarily transfer china diabete business astrazeneca gain base difference consideration allocate sale business exclude royalty net transaction fee carry value diabete business net asset include million allocation goodwill reversal million net defer tax liability attribute amylin consideration million receive transfer mount vernon indiana manufacturing facility relate inventory result gain million amount allocate deliver element consideration allocate development supply agreement continue amortize applicable service period amortization defer income attribute development agreement include income sale service consider bmss ongoing major central operation revenue attribute supply agreement include alliance revenue consideration transaction present cash flow purpose base allocation process describe invest activity attribute sale business relate asset operating activity attribute transitional service supply arrangement development agreement september bm transfer percentage future royalty right amylin net product sale cppib credit europe sarl luxembourg private limited liability company cppib transfer right represent approximately potential future royalty bms entitle exchange transfer bms receive additional tieredbase royalty amylin net product sale cppib include income earn summarize financial information relate astrazeneca alliance follow year end december dollar millions revenue astrazeneca alliance net product sale alliance revenue total revenue payment tofrom astrazeneca cost product sell profit sharing amortization defer income cost reimbursement tofrom astrazeneca recognize cost product sell marketing sell administrative research development incomeexpense amortization defer income provision restructure royalty transitional service gain sale business select alliance cash flow information defer income divestiture proceed select alliance balance sheet information december dollar millions defer income attribute asset transfer astrazeneca service perform astrazeneca sanofi bms sanofi codevelopment cocommercialization agreement plavix avaproavalide effective january sanofi assume essentially worldwide operation alliance exception plavix puerto rico bms operating partner control interest exchange right transfer sanofi bms receive quarterly royalty january december terminal payment sanofi million end royalty receive sanofi territory cover americas australia optout market development royalty present alliance revenues million million million royalty attribute territory cover europe asia continue earn territory partnership include equity net income affiliate alliance revenue attribute supply irbesartan api sanofi million million million supply arrangement irbesartan expire summarize financial information relate alliance follow year end december dollar millions revenue sanofi alliance net product sale alliance revenue total revenue payment tofrom sanofi equity net income affiliate noncontrolle interest pretax select alliance cash flow information distribution tofrom sanofi noncontrolle interest distribution sanofi investment affiliate select alliance balance sheet information december dollar million investment affiliate territory cover europe asiaa noncontrolle interest include alliance receivables follow summarize financial information interest partnership sanofi territory cover europe asia consolidated account equity method year end december dollar million net sale gross profit net income cost product sell territory cover europe asia include discovery royalty million million million pay directly sanofi expense share base applicable ownership percentage current asset current liability include approximately million million million relate receivablespayable attribute cash distribution bms sanofi intercompany balance partnership territory ono bms principal end customer product sale exclusive right develop manufacture commercialize opdivo antipd human monoclonal antibody investigate anticancer treatment territory worldwide japan south korea taiwan ono pharmaceutical ltd ono responsible development commercialization prior arrangement describe ono entitle receive royalty follow regulatory approval territory exclude country list royalty rate net sale north america applicable territory subject customary adjustment alliance arrangement expand july establish collaboration activity japan south korea taiwan pertain opdivo bms compound include yervoy lirilumab urelumab bms antilag party right obligation jointly develop commercialize compound bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono alliance codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay party sale partys assign customer summarize financial information relate alliance follow year end december dollar millions revenue ono alliance net product sale alliance revenue total revenue payment tofrom ono cost product sell copromotion fee profit sharing cost reimbursement ono abbvie bms abbvie inc abbvie alliance empliciti humanize monoclonal antibody treatment multiple myeloma term alliance bms grant exclusive global right codevelop commercialize empliciti pdl biopharma inc abbvie abbvie currently participate joint development commercialization committee bms final decision make authority party codevelope product abbvie fund global development cost bms solely responsible supply distribution sale marketing activity alliance principal end customer product sale abbvie share profit loss pay tiere royalty net sale empliciti outside addition abbvie entitle receive milestone payment bms certain regulatory event sale threshold achieve agreement terminate bms subsequent notice period party material breach party financial information relate alliance material year end december fstar october bms enter agreement fstar alpha ltd fstar agreement provide bms exclusive option purchase fstar phase ready lead asset target therapy development treatment breast gastric cancer welldefine population herpositive patient bms pay million fstar shareholder consideration option grant certain licensing right include research development expense responsible conducting funding development option exercisable bms discretion expire early day follow obtain proof concept june additional million payable exercise option plus additional aggregate consideration million contingent development regulatory approval milestone payment europe bms obligate provide additional financial support fstar fstar determine business define asc business combination result contingent consideration include purchase price goodwill recognize fstar variable interest entity equity holder lack characteristic control financial interest bms determine primary beneficiary power direct activity significantly directly impact economic performance entity option right describe consolidation noncontrolle interest credit million reflect fair value iprd asset million defer tax liability promedior september bms purchase warrant give bms exclusive right acquire promedior inc promedior biotechnology company lead asset prm develop treatment idiopathic pulmonary fibrosis ipf myelofibrosis warrant exercisable completion ipf phase clinical study conduct promedior expect occur early upfront payment allocate warrant million include research development expense quarter remain million million upfront payment allocate promedior obligation complete phase study amortize expect period phase study allocation determine level input follow bms review phase clinical study result bms elect exercise warrant obligate pay additional million base ipf study result million base study result plus additional aggregate consideration million contingent development regulatory approval milestone payment europe prime november bms prime therapeutic inc prime enter exclusive worldwide licensing collaboration agreement development commercialization prime colony stimulate factor receptor csfr antibody program include fpa currently phase development immunology oncology indication bms responsible development manufacturing commercialization fpa subject prime option conduct certain study cost develop fpa pigment vilonodular synovitis pvns combination internal oncology pipeline asset prime retain option copromote agreement replace previous clinical collaboration agreement party consideration licensing right bms upfront payment million fourth quarter include research development expense bms commit pay billion achievement contingent development regulatory milestone future royalty product approve commercialize reckitt benckiser group bms reckitt benckiser group plc reckitt start threeyear alliance overthecounterproduct sell primarily mexico brazil reckitt receive right sell distribute market product bms receive royalty net sale product exclusively supply certain product reckitt pursuant supply agreement cost plus markup certain limited asset include market authorization certain employee directly attribute business transfer reckitt start alliance period bms retain ownership asset relate business include trademark cover product framework alliance bms grant reckitt option acquire trademark inventory certain asset exclusively relate product end alliance period price determine primarily base multiple sale april alliance modify provide option reckitt purchase bms manufacturing facility locate mexico primarily dedicated product include alliance july reckitt notify bms exercise option substantially employee facility expect transfer reckitt closing expect occur refer note asset heldforsale information nonrefundable upfront proceed million receive bms allocate unit account include right transfer reckitt fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include liability bms recognize income million decrease fair value option zero strengthen dollar local currency anticipate proceed expect approximate fair value asset transfer allocate right transfer reckitt amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenues reckitt alliance alliance revenues select alliance cash flow information defer income change operate asset liability select alliance balance sheet information december dollar millions defer income medicine company february bms medicine company enter twoyear alliance recothrom recombinant thrombin use topical hemostat control nonarterial bleed surgical procedure previously acquire bms connection acquisition zymogenetics inc medicine company receive right sell distribute market recothrom global basis year bms exclusively supply recothrom medicine company cost plus markup receive royalty net sale recothrom certain employee directly attribute business certain asset transfer medicine company start alliance period include biologic license application relate regulatory asset bms retain asset relate recothrom include patent trademark inventory bms grant medicine company option acquire patent trademark inventory certain asset exclusively relate recothrom price determine base multiple sale plus cost remain inventory hold bms time medicine company exercise option acquire business million february refer note asset heldforsale information nonrefundable upfront proceed million receive bms allocate unit account include right transfer medicine company fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option million december determine level input include accrue expense allocate right transfer medicine company amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenue medicines company alliance alliance revenues incomeexpense gain sale business select alliance cash flow information defer income change operate asset liability divestiture proceed select alliance balance sheet information december dollar millions deferred income valeant october bms pharmaswis whollyowne subsidiary valeant pharmaceuticals international inc valeant enter alliance certain mature brand product europe valeant receive right sell distribute market product europe december bms exclusively supply product valeant cost plus markup bms grant valeant option acquire trademark intellectual property exclusively relate product price determine base multiple sale valeant exercise option acquire business million january refer note asset heldforsale information nonrefundable upfront proceed million receive bms allocate unit account include right transfer valeant fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include accrue expense million charge include expense increase fair value option million allocate right transfer valeant amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenue valeant alliance net product sale alliance revenue total revenue incomeexpense gain sale business select alliance cash flow information change operate asset liability divestiture proceed note acquisition divestitures cardioxyl acquisition december bms acquire outstanding share cardioxyl pharmaceuticals inc cardioxyl privately hold biotechnology company focus discovery development novel therapeutic agent cardiovascular disease acquisition provide bms right cxl nitroxyl prodrug phase development acute decompensate heart failure consideration include upfront payment million contingent development regulatory salesbase milestone payment billion significant cardioxyl process acquire transaction account asset acquisition cardioxyl determine business term define asc business combination consideration allocate cxl result million research development expense net operating loss tax credit carryforward result million defer tax asset flexus acquisition april bms acquire outstanding share flexus biosciences inc flexus privately hold biotechnology company focus discovery development novel anticancer therapeutic acquisition provide bms right preclinical small molecule idoinhibitor target immunotherapy addition bms acquire flexus idotdo discovery program include idoselective idotdo dual tdoselective compound consideration include upfront payment million plus acquisition cost contingent development regulatory milestone payment million significant flexus process acquire transaction account asset acquisition flexus determine business consideration allocate idotdo discovery program result million research development expense net operating loss tax credit carryforward result million defer tax asset ipierian acquisition april bms acquire outstanding share ipierian inc ipierian biotechnology company focus new treatment tauopathie class neurodegenerative disease acquisition provide bms right ipn preclinical monoclonal antibody treat progressive supranuclear palsy tauopathie consideration include upfront payment million contingent development regulatory milestone payment million future royalty net sale acquire preclinical asset approve commercialize significant ipierian process acquire transaction account asset acquisition ipierian determine business consideration allocate ipn result million research development expense net operating loss tax credit carryforward result million defer tax asset divestiture addition divestiture transaction astrazeneca lilly medicines company valeant discuss note alliance bms divest ixempra business business product line transaction generate net proceed million result pretax gain million include million defer gain additional contingent proceed recognize earning receive revenue pretax earning relate business material note asset heldforsale december bms agree sell pipeline investigational hiv medicine viiv healthcare include number program different stage discovery preclinical clinical development transaction exclude bmss hiv market medicine certain bms employee offer opportunity transfer viiv healthcare bms provide certain service transitional period transaction expect close half obtain customary regulatory approval account sale business consideration include upfront payment million contingent development regulatory milestone payment billion salesbase milestone payment billion future royalty product approve commercialize bms reimburse service asset heldforsale million december comprise primarily goodwill relate investigational hiv business business comprise alliance reckitt asset heldforsale million december comprise inventory goodwill intangible asset relate business comprise alliance medicine company valeant allocation goodwill base relative fair value business divest company reporting unit note incomeexpense incomeexpense include year end december dollar million interest expense investment income provision restructure litigation settlement equity net income affiliate outlicense intangible asset impairment gain sale business product line assets alliance license income pension charge loss debt redemption incomeexpense litigation settlement include million contractual dispute relate license include unrealized foreign exchange loss million result remeasurement bolivardenominate cash monetary balance bmss whollyowne subsidiary venezuela december exchange rate change simadi rate official cencoex rate consider limited foreign currency exchange second half publish exchange rate continue deterioration economic condition venezuela note restructuring follow provision restructuring year end december dollar million employee termination benefit exit cost provision restructure restructuring charge include employee termination benefit manufacturing sell administrative research development workforce reduction geographic region approximately restructure action primarily relate specialty care transformation initiative design create simplify organization function geographic market sale force reduction european country follow restructure sanofi otsuka alliance agreement subject local regulation cost recognize completion discussion work council follow table represent activity employee termination exit cost liability year end december dollar million liability january charge change estimate provision restructure foreign currency translation liability relate asset heldforsale spending liability december note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provision effective tax rate reconciliation effective taxbenefit rate statutory federal income tax rate earning income taxis dollar million earningsloss income taxis nonus total statutory rate foreign tax effect certain operation ireland puerto rico switzerland tax effect capital loss valuation allowance release federal state foreign contingent tax matter federal research base credit goodwill allocate divestiture brand prescription drug fee charge state local taxis net valuation allowance foreign effective tax rate low statutory rate primarily attributable undistributed earning certain foreign subsidiary consider expect indefinitely reinveste offshore taxis provide approximately billion undistributed earning foreign subsidiary december undistribute earning primarily relate operation switzerland ireland puerto rico undistribute earning repatriate future determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide reform tax law relate foreign earning propose adopt increase taxis reduce result operation cash flow bms operate favorable tax grant puerto rico schedule expire prior divestiture certain business result capital loss tax benefit include million sale amylin share valuation allowance attribute capital loss carryforward release follow divestiture recothrom ixempra mature brand additional reserve million establish certain transfer pricing matter related tax period retroactive reinstatement federal research development credit result additional tax credit million orphan drug credit include federal research base credit period present goodwill allocate business divestiture include diabetes business deductible tax purpose brand prescription drug fee period research development charge result primarily acquisition flexus cardioxyl ipierian deductible tax purpose defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward capital loss carryforward state net operating loss credit carryforward federal net operating loss credit carryforward defer income milestone payment license fee pension postretirement benefit intercompany profit inventory item foreign defer tax asset sharebase compensation legal settlement repatriation foreign earning internal transfer intellectual property total defer tax asset valuation allowance defer tax asset net valuation allowance defer tax liability depreciation acquire intangible asset goodwill total defer tax liability defer tax asset net recognize deferred income taxis current deferred income taxis noncurrent income taxis payable current income taxis payable noncurrent total company elect early adopt accounting standard update december prospective basis result defer taxis report noncurrent balance sheet internal transfer intellectual property result defer tax asset million prepay taxis million include asset december asset amortize expect live federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin federal tax credit carryforward expire vary amount begin realization federal tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration capital loss carryforward available million dependent generating sufficient domesticsource capital gain income schedule expire foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life december valuation allowance million establish follow item million primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal net operating loss carryforward million federal capital loss million federal defer tax asset change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisition balance end year income tax payment million million million current tax benefit realize result stock relate compensation credit capital excess par value stock million million million business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follow year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty interest expense penalty expensebenefit accrue interest penalty payable unrecognized tax benefit include current noncurrent income taxis payable interest penalty relate unrecognized tax benefit include income tax expense bms currently examination number tax authority include limited major tax jurisdiction list table propose consider propose material adjustment tax issue transfer price certain tax credit deductibility certain expense bms estimate reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit primarily settlement related involve payment additional taxis adjustment certain defer taxis andor recognition tax benefit reasonably possible new issue raise tax authority increase unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico note earning share year end december amount million share datum net earning attributable bms basic diluted eps calculation weightedaverage common share outstanding basic contingently convertible debt common stock equivalent incremental share attributable sharebased compensation plan weightedaverage common share outstanding diluted earning share basic earning share dilute note financial instrument fair value measurement financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input level input utilize observable price similar instrument quote price identical similar instrument nonactive market additionally certain corporate debt security utilize thirdparty matrix pricing model significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective net asset value underlie investment significant unfunded commitment restriction redemption relate equity fix income fund december level derivative instrument value london interbank offer rate libor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably volatility underlie foreign currency underlie interest rate drive market condition duration contract level unobservable input little market datum available fair value write option acquire outstanding share sell asset certain business refer note alliance discussion base option pricing methodology consider revenue profitability projection volatility discount rate potential exercise price assumption financial asset liability measure fair value recur basis summarize december december dollar million level level level total level level level total cash cash equivalent money market security marketable security certificate deposit corporate debt security equity fund fix income fund auction rate security ar derivative asset interest rate swap contract forward start interest rate swap contract foreign currency forward contract equity investment derivative liability interest rate swap contract forward start interest rate swap contract foreign currency forward contract write option liability contingent consideration liability follow table summarize activity financial asset utilize level fair value measurement write contingent write contingent option consideration option consideration dollar million ar liability liability ar liabilitie liability fair value january realize loss sale settlement change fair value fair value december availableforsale security follow table summarize availableforsale security gross gross unrealize unrealized gain loss amortize accumulate accumulate dollar million cost oci oci fair value december certificate deposit corporate debt security equity investment total december certificate deposit corporate debt security ar equity investment total availableforsale security include current marketable security million december million december non current availableforsale corporate debt security mature year december equity investment million million include asset december respectively fair value option financial asset investment equity fix income fund offset change fair value certain employee retirement benefit include current marketable security change fair value significant qualifying hedge follow summarize fair value outstanding derivative december december dollar million balance sheet location notional fair value notional fair value derivative designate hedge instrument interest rate swap contract asset interest rate swap contract liability forward start interest rate swap contract asset forward start interest rate swap contract liabilitie foreign currency forward contract prepay expense foreign currency forward contract asset foreign currency forward contract accrue expense cash flow hedge foreign currency forward contract hedge certain forecast intercompany inventory purchase transaction certain foreign currency transaction effective portion change fair value contract designate cash flow hedge temporarily report accumulate comprehensive loss include earning hedge item affect earning net gain foreign currency forward contract expect reclassify net earning primarily include cost product sell year notional outstanding foreign currency forward contract primarily attribute euro million japanese yen million december fair value foreign currency forward contract attribute japanese yen notional million designate cash flow hedge million include accrue expense december bm enter million forward start interest rate swap contract mature march hedge variability probable forecast interest expense associate potential future issuance debt contract designate cash flow hedge effective portion fair value change include comprehensive income earning impact relate discontinued cash flow hedge hedge ineffectiveness significant period present cash flow hedge accounting discontinue forecast transaction long probable occur day originally forecast date hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis net investment hedge nonus dollar borrowing million million designate hedge foreign currency exposure net investment certain foreign affiliate borrowing designate net investment hedge recognize long term debt effective portion foreign exchange gain loss remeasurement debt recognize foreign currency translation component accumulate comprehensive loss relate offset longterm debt fair value hedge fixedtofloate interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt contract underlie debt hedge benchmark risk record fair value effective interest rate contract onemonth libor december plus interest rate spread range underlying swap terminate prior maturity fair value basis adjustment underlie debt instrument amortize reduction interest expense remain life debt notional fixedtofloate interest rate swap contract execute million billion notional fixedto float interest rate swap contract terminate million million generating proceed million million include accrue interest million million additional contract terminate connection debt redemption debt obligation shortterm borrowing million million december respectively consist primarily bank overdrafts average commercial paper outstanding million weightedaverage interest rate maximum month end commercial paper outstanding million outstanding borrowing december borrowing longterm debt include december dollar millions principal value euro note note note euro note note debenture note euro note debenture euro note note note note note debenture mature subtotal adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount issuance costsa total exclude unamortized bond issuance cost million reclassify december fair value longterm debt million million december respectively estimate base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument senior unsecured note issue register public offering notes rank equally right payment bms exist future senior unsecured indebtedness redeemable time predetermine redemption price bms terminate forward start interest rate swap contract enter result unrealized loss comprehensive income follow table summarize note issuance amount million euro dollar dollar principal value note note euro note euro note note total proceed net discount defer loan issuance cost forward start interest rate swap contract terminate notional unrealized gainloss company repurchase million longterm debt cash tender offer redeem billion billion longterm debt follow issuance new senior unsecured note connection debt redemption activity certain interest rate swap contract enter terminate second quarter debt redemption debt redemption activity follow dollar million principal carry value debt redemption price notional interest rate swap contract terminate interest rate swap termination payment loss debt redemptiona include acceleration debt issuance cost loss interest rate lock contract relate fee note principal million mature repay interest payment million million million net amount receive interest rate swap contract separate billion fiveyear revolve credit facility maintain syndicate lender facility provide customary term condition financial covenant extendable anniversary date consent lender borrowing outstanding revolve credit facility december financial guarantee provide form standby letter credit performance bond million december standby letter credit issue financial institution support guarantee obligation performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority outstanding financial guarantee expire year expect fund note receivable december dollar million trade receivable allowance net trade receivables alliance partner receivables prepaid refundable income taxis miscellaneous receivables receivables nonus receivables sell nonrecourse basis million million million aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively change allowance bad debt chargeback cash discount follow year end december dollar million balance begin year provision utilization asset heldforsale balance end year note inventory december dollar million finished good work process raw packaging material inventory inventory expect remain onhand year include million inventory pende regulatory approval include asset million december million december note property plant equipment december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment mount vernon indiana manufacturing facility transfer astrazeneca quarter connection sale diabete business facility gross property plant equipment million date transfer million net accumulate depreciation refer note alliance discussion sale diabete business fully depreciate bulk manufacturing facility cease use result million reduction gross property plant equipment accumulate depreciation depreciation expense million million million note goodwill intangible asset december estimate dollar million useful life goodwill intangible asset license year develop technology right year capitalize software year inprocess research development iprd gross intangible asset accumulate amortization total intangible asset reduction goodwill result allocation amount business divestiture refer note alliance note acquisition divestiture note asset heldforsale discussion divestiture amortization expense million million million future annual amortization expense intangible asset expect approximately million million million million million intangible asset impairment charge million million license million million net accumulate amortization derecognize result transfer erbitux north american business lilly october refer note alliance discussion million iprd impairment charge recognize bms lysophosphatidic acid receptor antagonist phase development treatment ipf writeoff require consider occurrence certain adverse event voluntary suspension study internal assessment indicate significantly low likelihood regulatory commercial success bms acquire bms acquisition amira pharmaceuticals inc addition contingent consideration liability million relate acquisition reverse low likelihood success million iprd impairment charge recognize peginterferon lambda phase iii development treatment hepatitis virus hcv writeoff require assess potential commercial viability asset estimate fair value assessment consider low likelihood file registration certain market complete revise projection revenue expense significant decline prior project revenue result global introduction oral noninterferon product treat patient hcv alternative use product note accrue expense december dollar million employee compensation benefit royaltie accrue research development restructure current pension postretirement benefit litigation settlement total accrue expense note sale rebate return accrual reduction trade receivable accrue rebate return liability follow december dollar million chargeback relate government program cash discount reduction trade receivables medicaid medicare rebate sale return rebate discount adjustment accrue rebate return note deferred income december dollar million alliance note total defer income current portion noncurrent portion alliance include unamortized amount upfront milestone licensing receipt revenue deferral attribute gilead alliance defer income undelivered element diabete business divestiture upfront milestone licensing receipt amortize short contractual right period expect life product deferral include approximately million invoice daklinza early access program france december defer final pricing obtain french government amortization defer income million million million note equity common stock capital treasury stock excess par value retain noncontrolle dollar share million share par value stock earning share cost interest balance january net earning cash dividend declare stock repurchase program employee stock compensation plan distribution balance december net earning cash dividend declare employee stock compensation plan debt conversion variable interest entity distribution balance december net earning cash dividend declare employee stock compensation plan debt conversion distribution balance december treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method component comprehensive incomeloss follow dollar million pretax tax tax derivative qualify cash flow hedgesa unrealize gain reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial gain amortizationb settlementsc pension postretirement benefit availableforsale security unrealize loss realize gainsc availableforsale security foreign currency translation derivative qualify cash flow hedgesa unrealize gain reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial loss amortizationb settlement curtailmentsc pension postretirement benefit availableforsale security unrealize gain realize gainsc availableforsale security foreign currency translation derivative qualify cash flow hedgesa unrealize gain reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial loss amortizationb settlement curtailmentsc pension postretirement benefit availableforsale security unrealize loss realize loss availableforsale security foreign currency translation include cost product sell include cost product sell research development marketing sell administrative expense include incomeexpense accumulate balance relate component comprehensive loss net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation accumulate comprehensive loss note pension postretirement postemployment liabilitie bms sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan cover employee represent approximately consolidated pension plan asset obligation future benefit relate service plan eliminate bms contribute minimum require employee retirement income security act erisa plan benefit base primarily participant year credit service final average compensation plan asset consist principally equity fixedincome securities comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome security net periodic benefit costcredit define benefit pension postretirement benefit plan include pension benefit benefit dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service credit amortization net actuarial gainloss curtailment settlement special termination benefit net periodic benefit costcredit september bms fiduciary counselors inc independent fiduciary bristolmyers squibb company retirement income plan enter definitive agreement transfer certain pension asset prudential insurance company america prudential settle approximately billion pension obligation bms purchase group annuity contract prudential december irrevocably assume obligation future annuity payment certain bms retiree transaction change monthly pension benefit receive affected retiree survive beneficiary result pretax settlement charge million pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan change define benefit postretirement benefit plan obligation asset fund status amount recognize consolidated balance sheet follow pension benefit benefit dollar million benefit obligation begin year service costbenefit earn year interest cost plan participant contribution curtailment settlement plan amendment actuarial gainslosses retiree drug subsidy benefit pay exchange rate gain benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement retiree drug subsidy benefit pay exchange rate loss fair value plan asset end year fund status assetsliabilitie recognize asset accrue expense pension postretirement liability fund status recognize accumulate comprehensive loss net actuarial gainslosse prior service credit total accumulate benefit obligation define benefit pension plan million million december respectively additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine benefit obligation december follow pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit creditcost year end december follow pension benefit benefit discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citigroup pension discount curve develop discount rate plan expect return plan asset determine expect rate return calculate value asset refer marketrelated value marketrelate value plan asset exceed fair value approximately million december difference assume actual return amortize marketrelated value straightline basis threeyear period factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year actuarial gain loss result change actuarial assumption change discount rate revise mortality rate difference assume actual experience difference actual expect return plan asset gain loss amortize life expectancy plan participant plan year expect remain service period plan extent exceed high marketrelated value project benefit obligation respective plan amortization net actuarial loss prior service credit expect approximately million periodic benefit cost credit include cost product sell research development marketing sell administrative expense curtailment settlement special termination benefit include expense assume healthcare cost trend rate december follow healthcare cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate onepercentagepoint change assume healthcare cost trend rate material impact cost benefit obligation plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total equity security equity fund fix income fund corporate debt security venture capital limit partnership treasury agency security shortterm investment fund insurance contract event drive hedge fund cash cash equivalent total plan asset fair value investment valuation policy investment class follow level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input instrument include equity security equity fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input utilize observable price similar instrument quote price identical similar instrument nonactive market observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund event drive hedge fund shortterm investment fund classify level fair value hierarchy value net asset value share hold year end significant unfunded commitment restriction redemption relate investment value nav december corporate debt security treasury agency security classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available venture capital limit partnership classify level fair value hierarchy invest underlying security market value determine pricing model discount cash flow methodology similar technique significant unobservable input valuation methodology include discount rate earning interest taxis depreciation amortization ebitda multiple revenue multiple significant change input result significantly lower high fair value measurement insurance contract hold certain foreign pension plan carry contract value approximate estimate fair value base fair value underlie investment insurance company follow summarize activity financial asset utilize level fair value measurement venture capital limited insurance dollar million partnership contract total fair value january purchase sale settlement net realize gainslosse unrealize gainslosse fair value december purchase sale settlement net realize gainslosse unrealize loss fair value december investment strategy emphasize equity order achieve higher expect return low expense require cash contribution longterm target asset allocation public equity international global private equity longduration fix income maintain pension plan investment diversify major asset category approximately pension plan equity investment actively manage venture capital limited partnership typically value month lag late available information bms common stock represent plan asset december contribution estimate future benefit payment contribution pension plan million million million expect approximately million estimate annual future benefit payment include lump sum payment range million million year aggregate billion subsequent year period saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match expense attribute define contribution plan approximately million note employee stock benefit plan shareholder approve stock award incentive plan plan replace stock incentive plan plan provide million share authorize grant plus share outstanding award plan february expire forfeit cancel withhold satisfy tax withholding obligation december million share available award share issue treasury stock satisfy obligation plan executive officer key employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price company grant stock option stock appreciation right restrict stock unit grant key employee subject restriction continuous employment generally vest occur ratably year period grant date compensation expense recognize vest period stock unit right receive stock end specify vest period voting right market share unit grant executive vest condition continuous employment vest date payout factor share price award date payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur ratably year performance share unit grant executive year cycle grant target number unit subject adjustment base company performance number share issue performance share unit vest determine base achievement annual performance goal number share issue performance share unit award adjust base company threeyear total shareholder return relative peer group company vest occur anniversary grant date stockbase compensation expense award ultimately expect vest recognize vest period forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate information relate stockbase compensation benefit follow year end december dollar million stock option restrict stock unit market share unit performance share unit total stockbase compensation expense income tax benefit stock option restrict stock unit market share unit performance share unit weight number weight number weight number weight number average average average average option exercise price nonveste grantdate nonveste grantdate nonveste grantdate share thousand outstanding share awards fair value award fair value award fair value balance january grant releasedexercised adjustment actual payout forfeitedcancele balance december vest expect vest restrict market performance dollar million stock unit share unit share unit unrecognize compensation cost expect weightedaverage period year compensation cost recognize amount million share datum weightedaverage grant date fair value share restrict stock unit market share unit performance share unit fair value option award vest year stock option restrict stock unit market share unit performance share unit total intrinsic value stock option exercise year fair value award approximate close trading price bms common stock grant date fair value market share unit consider payout formula probability satisfy market condition follow table summarize significant range outstanding exercisable option december option outstanding exercisable number weightedaverage weightedaverage aggregate outstanding exercisable remain contractual exercise price intrinsic value range exercise price thousand life year share million aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december note lease annual minimum rental commitment noncancelable operating lease primarily real estate motor vehicle approximately million year aggregate million operate lease expense approximately million sublease income material period present note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business claim proceeding involve type party include government competitor customer supplier service provider licensee employee shareholder resolution matter develop long period time expectation change result new finding ruling appeal settlement arrangement company recognize accrual contingency probable liability incur loss reasonably estimate matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial contractual right licensing obligation health safety matter consumer fraud employment matter product liability insurance coverage legal proceeding material company believe material describe company believe substantial defense matter assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material note company unable assess outcome respective litigation able provide estimate range potential loss furthermore failure enforce patent right likely result substantial decrease respective product revenue generic competition intellectual property baraclude south korea daewoong pharmaceutical ltd hanmi pharmaceuticals ltd donga pharmaceutical ltd generic company initiate separate invalidity action korean intellectual property office korean patent patent cover entecavir molecule january korean intellectual property tribunal rule patent valid decision affirm appeal september patent court patent expire october follow expiration patent generic company enter south korean market expect continue decline net product sale baraclude plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate tablets australia genrx subsidiary apotex inc apotex change apotex august apotex file application federal court australia federal court seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september court hold claim patent invalid november company sanofi apply high court australia high court special leave appeal judgment court march high court deny company sanofis request hear appeal court decision case remand federal court proceeding relate damage seek apotex australian government intervene matter seek damage allege loss experience period injunction place company apotex settle apotex case case dismiss australian government claim pende possible time predict outcome australian government claim impact company eliquis interparte review ipr august bristolmyers squibb receive petition inter parte review patent patent file united states patent trademark office coalition affordable drug affiliate entity individual associate hedge fund patent composition matter patent contain claim direct apixaban active ingredient eliquis petition request patent trial appeal board ptab initiate proceeding review validity patent include claim cover apixaban company respond opposed petition november ptab expect render decision initiate proceed midfebruary ptab decide initiate proceeding decision merit expect half company intends vigorously defend patent challenge patent expire february company file request patent term restoration patent trademark office request patent expiration date restore december sprycel european union apotex actavis group ptc ehf generics limited mylan unnamed company file opposition european patent office epo seek revocation european patent patent cover dasatinib active ingredient sprycel patent schedule expire april exclude potential term extension january opposition division epo revoke patent company appeal epos decision epo board appeal patent remain force pende outcome appeal epos decision intend pursue legal option defend intellectual property right future infringement orphan drug exclusivity datum exclusivity sprycel expire november decision affect validity sprycel patent outside europe include different patent cover monohydrate form dasatinib company enter settlement agreement apotex patent infringement suit apotex launch generic dasatinib monohydrate abbreviate new drug application product september early certain circumstance antipd antibody patent opposition litigation bring claim infringement number ongoe patent litigation merck inc merck world respect patent direct method treat cancer antibody alliance ono bms exclusive right patent include european patent patent merck file opposition european patent office epo seek revocation patent june opposition division epo maintain validity claim patent merck appeal decision merck file lawsuit united kingdom seek revocation national version patent july bms ono sue merck patent infringement trial hold july october court issue judgment find patent valid infringe merck appeal judgment february merck file lawsuit netherlands seek revocation dutch national version patent bms ono subsequently sue merck patent infringement trial validity infringement patent hold january decision dutch court pende december bms ono file lawsuit respect national version patent european country include france germany ireland spain switzerland bms ono file patent infringement action merck national courts europe time merck launch keytruda abovementione national court determine merck infringe valid claim patent bms ono entitle monetary damage include royalty future sale keytruda bms ono seek injunction prevent merck marketing keytruda litigation appropriate financial remedy agree award court september bms ono file lawsuit united states allege merck marketing keytruda infringe patent patent trial matter currently schedule begin april june july bms ono file lawsuit united states allege merck marketing keytruda infringe patent nos patent patent respectively patent relate patent lawsuit bms ono seek prevent stop market keytruda united states appropriate financial remedy agree award court april merck company oppose european patent patent direct class antipd antibodie february bms ono submit request amend claim patent oral proceeding opposition division epo schedule july september merck file lawsuit australia seek revocation australian patent direct class antipd antibodie base application patent march bms ono countersued merck patent infringement ono bms similar patent application pende united states country september danafarber cancer institute danafarber file complaint massachusetts federal court seek correct inventorship relate patent specifically danafarber seeking add scientist inventor patent patent patent currently subject patent infringement proceeding file bms ono merck delaware federal court specify pricing sale promotional practice litigation awp litigation previously disclose company number pharmaceutical manufacturer defendant number private class action suit bring attorney general state action plaintiff allege defendant cause average wholesale price awps product inflate injure government program entity person reimburse prescription drug base awps company remain defendant state attorney general suit pende state court pennsylvania wisconsin company designate defendant separate trial wisconsin settlement reach company defendant hand state wisconsin begin august company defendant trial commonwealth court pennsylvania commonwealth court bring commonwealth pennsylvania september jury issue verdict company find company liable fraudulent negligent misrepresentation commonwealth court judge issue decision pennsylvania consumer protection claim jury find company liable million enjoin company contribute provision inflate awps company appeal decision pennsylvania supreme court june pennsylvania supreme court vacate commonwealth judge decision remand matter commonwealth court january commonwealth court enter judgment favor company commonwealth pennsylvania appeal decision pennsylvania supreme court affirm low court decision favor company december qui tam litigation march company serve unseal qui tam complaint file sale representative california superior court county los angeles california department insurance elect intervene lawsuit complaint allege company pay kickbacks california providers pharmacy violation california insurance frauds prevention act cal ins code december company california department insurance reach agreement financial term settlement principle party continue negotiation term final settlement plavix state attorney general lawsuit company certain affiliate sanofi defendant consumer protection andor false advertising action bring state relate sale promotion plavix possible time reasonably assess outcome lawsuit potential impact company product liability litigation company party product liability lawsuit plaintiff case seek damage relief ground allege personal injury economic loss previously disclose addition lawsuit company face unfiled claim involve product plavix previously disclose company certain affiliate sanofi defendant number individual lawsuit state federal court claim personal injury damage allegedly sustain plavix currently claim involve injury plaintiff claim spouse andor beneficiary file state federal court state include california new jersey delaware new york february judicial panel multidistrict litigation grant company sanofis motion establish multidistrict litigation coordinate federal pretrial proceeding plavix product liability relate case new jersey federal court possible time reasonably assess outcome lawsuit potential impact company reglan company number defendant numerous lawsuit behalf approximately plaintiff include injury plaintiff claim personal injury allegedly sustain reglan brand generic drug metoclopramide product indicate gastroesophageal reflux certain gastrointestinal disorder claim spouse andor beneficiary company generic subsidiary apothecon inc distribute metoclopramide tablet manufacture party possible time reasonably assess outcome lawsuit resolution pende lawsuit expect material impact company byetta amylin subsidiary company lilly codefendant product liability litigation relate byetta date separate lawsuit pende behalf active plaintiff include pende settlement include injury plaintiff claim spouse andor beneficiary court company agree principle resolve claim majority case bring individual allege personal injury sustain byetta primarily pancreatic cancer pancreatitis case claim alleged wrongful death majority case pende federal court san diego multidistrict litigation mdl coordinated proceeding california superior court los angeles jccp november defendant motion summary judgment base federal preemption grant mdl jccp plaintiff appeal court appeal ninth circuit case jccp formally dismiss amylin product liability insurance cover substantial number claim involve byetta additional liability amylin respect byetta expect share company astrazeneca possible reasonably predict outcome lawsuit claim proceed potential impact company shareholder derivative litigation december shareholder derivative lawsuit file new york state court certain officer director company plaintiff allege thing breach fiduciary duty surround company previously disclose october civil settlement securities exchange commission allege foreign corrupt practice act violation company agree payment approximately million disgorgement penalty interest government investigation like pharmaceutical company company certain subsidiary subject extensive regulation national state local government agency country bms operate result company time time subject governmental inquiry investigation possible criminal charge substantial fine andor civil penalty result government investigation significant investigation conduct government agency list abilify state attorney general investigation march company receive letter delaware attorney general office advise multistate coalition investigate certain abilify marketing practice violate respective state consumer protection statute possible time reasonably assess outcome investigation environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include comprehensive environmental response compensation liability act cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party north brunswick township board education previously disclose october company contact counsel represent north brunswick board education boe site waste material squibb son disposed fill material contain industrial waste heavy metal excess residential standard discover expansion project north brunswick township high school number neighbor residential property adjacent public park area january new jersey department environmental protection njdep send company information request letter possible waste disposal site company respond march boe township current owner school property park conduct jointly finance soil remediation work ground water investigation work work plan approve njdep ask company contribute cost company actively monitor cleanup project include cost date school board township assert claim company instead company local entity negotiate agreement attempt resolve matter informal mean avoid litigation central component agreement provision company interim funding help defray cleanup cost assure work interrupt company transmit interim funding payment december november party commence mediation late effort successful party move bind allocation process party expect conduct fact expert discovery follow formal evidentiary hearing write argument addition september township boe file suit party allege contribute waste material site litigation settle party company currently believe responsible additional amount interim payment total million transmit additional possible loss expect material note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earningsloss net earningsloss attributable noncontrolle interest bms earningsloss share basica earningsloss share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debt equity dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earningsloss attributable noncontrolle interest bms earning share basica earning share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debt equity earning share quarter add amount year period compute discrete basis marketable security include current noncurrent asset follow specify item affect comparability result second fourth dollar million quarter quarter quarter quarter year cost product solda marketing sell administrativeb license asset acquisition charge iprd impairment research development provision restructure gainloss sale business product line asset pension charge acquisition alliance relate item litigation settlement outlicense intangible asset impairment loss debt redemption incomeexpense increasedecrease pretax income income tax item increasedecrease net earning specify item cost product sell accelerate depreciation asset impairment shutdown cost specify item marketing sell administrative process standardization implementation cost second fourth dollar million quarter quarter quarter quarter year cost product solda additional year brand prescription drug fee process standardization implementation cost marketing sell administrative license asset acquisition charge iprd impairment research development provision restructure gainloss sale business product line asset pension charge acquisition alliance relate itemsb litigation settlement outlicense intangible asset impairment loss debt redemption upfront milestone licensing receipt incomeexpense increasedecrease pretax income income tax item specify tax chargec income taxis increasedecrease net earning specify item cost product sell accelerate depreciation asset impairment shutdown cost include million additional year brand prescription drug fee quarter specify tax charge relate transfer pricing matter report independent register public accounting firm board director shareholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting deloitte touche llp parsippany new jersey february item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include change internal control financial reporting change company internal control financial reporting quarter end december materially affect reasonable likely materially affect company internal control financial reporting item information report independent register public accounting firm board director shareholder bristolmyers squibb company audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement year end december company report date february express unqualified opinion consolidated financial statement deloitte touche llp parsippany new jersey february iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item information require item respect executive officer registrant include reliance general instruction instruction item regulation item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item item